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The aim of this study was to assess the extent on how effective was the prevention of 
mother-to-child transmission of Human Immunodeficiency Virus (HIV) infection at 
Oshakati District Health Centre. Explanatory survey was used to conduct the research. 
A total of 160 nurses experienced in prevention of mother-to-child transmission and 
women who attended antenatal care and post natal care services participated in the 
study. Respondents expressed unsatisfactory with the promoting involvement of male 
partners, high quality voluntary counselling and testing services, couple counselling and 
testing, integration of Highly Active Antiretroviral Therapy services, administration of 
short course of Zidovudine to pregnant mothers and the provision of antiretroviral drugs 
to infants. Therefore, promoting involvement of male partners, couple counselling and 
testing, administration of short course of Zidovudine to pregnant mothers and educating 
women about exclusive breastfeeding prior to delivery are some of recommendations 
for effective prevention of mother-to-child transmission of HIV infections.  
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The nature, scope and organisation of this study are discussed under the following 
headings: In the first instance the background to the study is given and flowing from that 
research problem is defined in the form of a problem statement. Secondly, the main 
research question is used to focus the assessment. For purposes of unpacking the 
research problem and maintaining coherence throughout the study. Thirdly, the 
methodology to attain the aim is given. Lastly, the scope and structure of the research 
study is presented. 
 
1.2 BACKGROUND INFORMATION ABOUT THE RESEARCH PROBLEM 
 
The Republic of Namibia conducted a sero-prevalence survey among pregnant women 
attending antenatal care (ANC) clinic for the first time in 1992 and then every second 
year. The result of the first survey reported a prevalence of 4.2% among pregnant 
women attending antenatal care clinic services and the country reached a peak of 22% 
in 2002 and has been declining thereafter with the latest being 18.8% in 2010 (Ministry 
of Health and Social Services [MoHSS] 2010:12).  With such high sero-prevalence 
among pregnant women, the World Health Organization (WHO) recommended 
strategies to reduce mother-to-child transmission of Human Immunodeficiency Virus 
(HIV) infection, using scientific evidence based interventions, which if implemented 
correctly can reduce mother-to-child transmission of HIV infection to below 2%–5% 
among non-breastfeeding and breastfeeding population respectively (WHO 2010a:6).  
 
In order to prevent mother-to-child transmission of HIV infection, the WHO (2008a:8) 





• Primary prevention of HIV infection among women of childbearing age 
• Preventing unintended pregnancies among women living with HIV 
• Preventing HIV transmission from a woman living with HIV to her infant 
• Providing appropriate treatment, care and support to mothers living with HIV and 
their children and families 
 
A study by United Nations Children's Fund (UNICEF) (2007:3) reveals that prevention of 
mother-to-child transmission of HIV infection (PMTCT) intervention is mainly focusing 
on the third component as WHO (2008a:8) indicates which is preventing the already 
infected mother from transmitting the HIV to her infant in utero, around the time of 
delivery and in the postpartum period. 
 
Magder, Mofenson, Paul, Zorrilla, Blattner, Tuomala, LaRussa, Landesman and Rich 
(2005:6) indicate that that mother-to-child transmission of HIV infection (MTCT) can 
occur in antepartum, intrapartum or postpartum through breast-feeding. Different factors 
may influence MTCT during each of these time periods and hence interventions to 
reduce transmission during each of these periods may also require different preventive 
strategies. 
 
1.2.1 The source of the research problem 
 
UNICEF reported that 1400 infants are infected with HIV during pregnancy, labour and 
delivery or breastfeeding every day. Unlike adults, infant infected with HIV report to 
have quicker progress to disease stage and 50% could die before 2 years of age if not 
initiated on treatment with antiretroviral prophylaxis (UNICEF 2008:5).To prevent this 
catastrophe, the WHO recommends full highly active antiretroviral therapy (HAART) to 
eligible pregnant women and antiretroviral (ARV) prophylaxis to those not eligible as 
indicated by WHO clinical staging or CD4 cell count. The call to use more efficacious 
regimen was adapted in Namibia late 2008, when the ministry of health pass a guideline 
to move away from giving single dose Nevirapine (NVP) at onset of labour to 
antepartum Zidovudine (AZT) from 28 weeks of pregnancy to all pregnant women not 
yet eligible to receive a full course of HAART. By end March 2009 Namibia had reached 
76% PMTCT coverage with a total of 340 health care facilities providing PMTCT 
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services (MoHSS 2008:3). HIV testing for infant using Deoxyribonucleic Acid 
Polymerase Chain Reaction (DNA PCR) from 6 weeks was also introduced late 2006.  
 
Apart from the pilot study done at the beginning of the PMTCT programme in Namibia, 
new recommendation have been adapted and implemented. Through clinical practice, 
mentoring of nurses in the PMTCT clinics and interaction with other health care 
professionals in PMTCT programmes, it become interesting to the researcher to 
conduct survey to assess the effectiveness of the PMTCT interventions at Oshakati 
District Health Centre. 
 
1.2.2 Outline to the research problem 
 
Oshakati District Health Centre has been facing challenges in PMTCT. The Centre has 
antepartum, intrapartum and postpartum HIV transmission prevention intervention 
programmes in place but the interventions are not effectively contributing to PMTCT. 
According to The Independent Expert Panel (2010:9), effective PMTCT requires a range 
of services since access to most interventions to reduce MTCT requires knowledge of 
maternal HIV serostatus, access to voluntary HIV testing and confidential counselling is 
critical. High uptake of testing can be achieved with routine provider-initiated HIV testing 
and counselling (PITC) combined with use of rapid tests offering same day results in 
antenatal and delivery settings.  
 
The Independent Expert Panel (2010:9) states that in the absence of PITC in ANC 
clinics, testing rates remain low, even where ANC attendance rates are high. While this 
is primarily due to lack of offering of the test, other factors are also involved including 
lack of test kits, inadequate counselling, need to discuss with male partner before 
making decision and fear of stigma. Provision of couple counselling and testing has 
been shown to increase acceptance of HIV testing by pregnant women.  
 
1.3 PROBLEM STATEMENT 
 
The PMTCT programme was implemented in Namibia in 2002, with two main goals, 
which were:  
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• Firstly, to ensure that 90% of HIV positive pregnant women, their children and 
partners had access to PMTCT services and receive a complete course of ARV 
prophylaxis to prevent MTCT. 
• Secondly, was to reduce the risk of MTCT from 30% to 15% (by 50%) by 2010.  
 
Like in other countries of the world, such as South Africa and Botswana just to mention 
a few, the Republic of Namibia’s interventions for PMTCT follow the four prongs 
approach as recommended by WHO (2008:8) but the result of the survey reported a 
prevalence rate of 18.8% among pregnant women attending ANC clinic services in 
2011. As a result, nearly 19 out of 100 babies at Oshakati District Health Centre are 
exposed to HIV and at risk of getting infected with HIV. Therefore a good understanding 
of the effectiveness of the following important interventions is crucial: 
 
• Antepartum HIV transmission prevention interventions 
 
A study by the WHO (2008:3) defines antepartum HIV transmission prevention 
interventions as an early identification of pregnant women living with HIV who require 
antiretroviral therapy (ART) for their own health and successful initiation of such drugs 
that improve the health and survival of mothers and significantly reduce infant and child 
mortality. 
 
WHO, UNAIDS and UNICEF (2009:97) further define antepartum HIV transmission 
prevention interventions as  a set of sequential interventions that include HIV testing 
and counselling (HCT) for pregnant women and their partners; clinical and 
immunological assessment to determine the eligibility of mothers for treatment and ART 
for eligible mothers for their own health and for their infants to prevent vertical 
transmission. 
 
Oshakati District Health Centre has challenges to achieve effective antepartum HIV 
transmission prevention interventions as women starts to attend antepartum services 
late in pregnancy mostly in the second and third trimester and some women do not 
attend antepartum services at all until delivery. This is influenced due to low community 
literacy level on PMTCT, cultural believes – not to disclose pregnancy too early and 
limited number of PMTCT trained nurses. As a result, Oshakati District Health Centre 
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experiences miss opportunities to PMTCT, delayed initiation of ART and prophylaxis 
and increase risk of MTCT in utero. 
 
• Intrapartum HIV transmission prevention interventions 
 
A study by the MoHSS (2008:13) defines intrapartum HIV transmission prevention 
interventions as management of the HIV positive woman during labour and delivery. 
The Ministry stresses that most infants who acquire HIV during labour and delivery do 
so by sucking, imbibing or aspirating maternal blood or cervical secretions that contains 
HIV. 
 
Oshakati District Health Centre has challenges to achieve effective intrapartum HIV 
transmission prevention interventions as a number of women still turns up in labour with 
unknown HIV status, some delivery on arrival to labour ward without ARV prophylaxis, 
and have not taken ARV prophylaxis during pregnancy, labour and delivery, they do not 
attend ANC clinic as scheduled and their babies are not given ARV prophylaxis at birth. 
This is influenced by women opted out to routine HIV testing, women drop ANC clinic 
visits, lack of knowledge on how the PMTCT programme works and fear of stigma if 
tested HIV positive. As a result, Oshakati District Health Centre experience missed 
opportunities of PMTCT, delayed initiation of ARV prophylaxis and increase risk of 
MTCT during labour and delivery. 
 
• Postpartum HIV transmission prevention interventions 
 
A study by the MoHSS (2008:14) defines postpartum HIV transmission prevention 
interventions as care of HIV-positive women after delivery that include treatment with 
antibiotics, reviewing and supporting the infant feeding option chosen, providing 
information on contraception options and women whose HIV status is not known are 
offered HCT in the immediate postnatal period once the patient has been stabilised. The 
MoHSS (2008:14) states that postpartum HIV transmission prevention interventions 
offers a window of opportunity to give ARV prophylaxis to the baby and counsel on 




The WHO (2009:97) further defines postpartum HIV transmission prevention 
interventions as counselling and support for feeding infants and young children in the 
context of HIV. The WHO (2009:97) indicates that HIV transmission prevention 
interventions are comprehensive care and support services that are particularly 
important for women with HIV infection and their families, who often face multiple social 
and medical challenges.  
 
Oshakati District Health Centre has challenges to achieve effective postpartum HIV 
transmission prevention interventions as infants are not initiated on breastfeeding 
immediately to promote bonding for mother who chose to breastfeed exclusively and no 
intensive infant feeding counselling is provided to HIV infected mothers. Most mothers 
and their children are not seen at 6 day and then after 6 weeks for postnatal care as 
recommended. Mothers are also not regularly monitored for HIV disease progression 
after delivery and most children do not have the first DNA PCR test at 6 weeks as per 
guideline. 
 
The interventions described above lead to main problem of this study, which is, what 
are the challenges affecting effective prevention of mother-to-child transmission of HIV 
infection? 
 
1.4 AIM OF THE STUDY 
 
The aim is to describe challenges to effective prevention of mother-to-child transmission 
of HIV infection interventions in order to effectively address identified challenges thus 






1.4.1 Research objectives 
 
The objectives of this study were to 
 
• Describe the challenges faced in the interventions for effective prevention of 
mother-to-child transmission of HIV infection in Namibia 
• describe the strategies used in the effective prevention of mother-to-child 
transmission of HIV infection 
• recommend effective measures to promote the interventions on the prevention of 
mother-to-child transmission of HIV infection in Namibia 
 
1.5 SIGNIFICANCE OF THE RESEARCH 
 
The researcher envisaged that the findings of this study would contribute towards the 
reduction of the spread of HIV infections through improvement of interventions for 
PMTCT programmes in Namibia. The research also examined how to improve and 
learn from challenges experienced in the past, and reference was made to various 
approaches utilised by other health facilities to achieve effective PMTCT within their 
areas of jurisdiction. Therefore, the advantages of effective PMTCT were explained. 
 
The research assisted in drawing and submitting conclusions and proposals that will 
contribute to the effective PMTCT. An additional, aspect was to provide 
recommendations that will contribute to Oshakati District Health Centre achieving 
expected effective PMTCT objectives. The research on effective PMTCT creates 
knowledge through which publicly available information will be shared with other health 
facilities. 
 
1.6 DEFINITIONS OF KEY CONCEPTS 
 
In the context of the study, certain key concepts that relate to the main problem 





1.6.1 Human Immunodeficiency Virus (HIV) 
 
According to the MoHSS (2010:1), HIV is a virus that weakens the immune system 
leaving the body vulnerable to diseases and causes AIDS.  
 
1.6.2 Prevention of mother-to-child transmission 
 
A programme aimed at preventing vertical transmission of HIV from the mother to her 
unborn baby or infant in utero, during labour and delivery and in the postpartum period 
including the breastfeeding period (UNICEF2010:3). In this study it means all 
interventions at Oshakati District Health Centre that are targeted to prevent HIV 
transmission from mother to her baby during pregnancy, labour and delivery and during 
postpartum. 
 
1.6.3 Antepartum HIV transmission prevention interventions  
 
McIntyre and Gray (2009:475) define antepartum HIV transmission prevention 
interventions as ANC services that are available and accessible at an early stage of 
pregnancy, to identify HIV-positive mothers and to provide ARV regimens. They indicate 
that antepartum services need to provide HCT, which must be acceptable to pregnant 
women to ensure uptake because high levels of acceptance of testing in pregnancy 
have been demonstrated in many high HIV-prevalence and low-resource areas. In this 
study it means the entire package of services that are recommended to reduce MTCT 
provided to women  when they attend antenatal care services at Oshakati District 
Health Centre that is targeted to prevent HIV transmission from mother to her baby 
during pregnancy, labour and delivery and during postpartum. 
 
A study by the WHO (2008a:3) defines antepartum HIV transmission prevention 
interventions as an early identification of pregnant women living with HIV who require 
ART for their own health and successful initiation of such drugs that improve the health 





1.6.4 Intrapartum HIV transmission prevention interventions 
 
Public Health Service Task Force (2009:59) defines intrapartum HIV transmission 
prevention interventions as the management of HIV-infected pregnant women during 
labour and delivery to minimise both the risk for perinatal HIV transmission and the 
potential for maternal and neonatal complications. In this study it means the entire 
package of services provided in labour and delivery room to reduce MTCT from the time 
the pregnant woman gets in true labour to delivery. This include safe obstetric practices 
the management of first, second and third stage of labour, and intervention with ARVs. 
 
Umerah-Udezulu and Williams (2006:44) further define intrapartum HIV transmission 
prevention interventions as protocol involving having HIV-positive women begin an 
antiretroviral regimen at the time of delivery. They state that intervention is dependent 
upon access to HVCT and adequate infrastructure to procure and administer ART 
drugs. 
 
1.6.5 Postpartum HIV transmission prevention interventions 
 
Bii, Otieno-Nyunya, Siika and Rotich (2008:158) define postpartum HIV transmission 
prevention interventions as determining the types and modes of infant feeding practices 
among the HIV infected mothers on PMTCT. In this study it means postpartum HIV 
prevention interventions provided during the early postpartum phase, this starts 
immediately after the third stage of labour to late postpartum.  
 
1.7 FOUNDATIONS OF THE STUDY 
 
Challenges facing effective PMTCT can be understood in terms of the theoretical issues 
















Figure 1.1 Critical activities for effective PMTCT model 
Source: Chopra (2008:19) 
 
According to Chopra (2008:19), as demonstrated in figure 1.1, key critical activities that 
need to happen in order to achieve the overall aim of PMTCT includes the presence of 
high quality HVCT service, regular supplies, increased community and individual 





Chopra (2008:19) states that PMTCT programme fulfils the following conditions: 
 
• Operational strategies and availability of financial resources: Policies, 
planning, protocols and co-ordination between the different management levels 
are necessary for an operational intervention. This must be supported by 
adequate financial resources. 
• Quality of the services and human resources: These are major elements of 
the final effectiveness of the intervention. Standard procedures have to be well 
designed and they have to be followed. Personnel must be positive, empathetic 
and compassionate. The criteria for counselling quality must be met. Human 
resource issues include availability of trained personnel, quality of training 
programmes and quality of follow up after training. 
• Availability of key resources and management systems: An uninterrupted 
supply of HIV tests, ARV and laboratory supplies must be guaranteed. This 
requires either procurement through the usual channels of drug supply or the 
establishment of a parallel system. This in turn requires functioning management 
systems. 
• Access and continued use of service. Women have to be able to get to the 
place where counselling, testing and treatment by ARV is offered.  
 
1.8 RESEARCH DESIGN AND METHODOLOGY 
 
Crosby, DiClemente and Salazar (2006:75) defined research design as “the strategy the 
investigator chooses for answering the research question”. The research question to be 
answered determined and helped the researcher identify the most appropriate research 
design used. 
 
1.8.1 Research design and method 
 
Research design is defined by Leedy and Ormrod (2010:91) as a framework or blueprint 
for conducting the research project. It specifies the details of the procedures necessary 
for obtaining the information needed to structure or solve research problems. The 
researcher’s first task was to make a decision on the type of research design to use. 
Therefore, the study employed exploratory design to measure the perceptions of HCWs 
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experienced in PMTCT and women who attended ANC and post natal care services at 
Oshakati District health Centre during one week of the research survey.  
 
This study used a quantitative approach. Data was collected through survey 
questionnaires. Questionnaires for patients were given to nurses in charge of Antenatal 
and postnatal unit for distribution to patients attending theses services and patient were 
directed to drop them in boxes which were closed with a "ballot box" like opening. All 
questionnaires for HCWs were handed over to HCWs by the researcher and HCWs 
were directed to drop them in a closed box. The researcher collected all questionnaires 
at the end of the data collection period.  
 
1.9 SCOPE OF THE STUDY  
 
This study included HCWs experienced in PMTCT and women who attended ANC and 
post natal care services at Oshakati District health Centre. HCWs not experienced in 
PMCTC were not surveyed. The convenient sampling applied makes results contained 
from study applicable to and limited to those units under study.  
 
1.10 STRUCTURE OF THE DISSERTATION 
 
The study consists of the following five chapters. 
 
• Chapter 1 presents the introduction, which includes the background to research 
problem, problem statement, aims of the study, research objectives, research 
questions and significance of the study. 
• Chapter 2 Present literatures reviewed related to the study. 
• Chapter 3 address the research methodology selected for this study including the 
data collection and data analysis methods. 
• Chapter 4 presents and analyses the results of the findings with respect to the 
challenges faced as well as the strategies deployed. It presents all findings in 
table and graphic form for each test item of the questionnaire and explains them. 
 
• Chapter 5 provides recommendations of the discussions of the findings as 
presented in the previous chapters, draw conclusions and implications of the 






This chapter has introduced the study by discussing the background information about 
the research problem, problem statement, aims of the study, significance of the 
research, definitions of key concepts, foundations of the study, research design and 
method, scope and structure of the study. Findings of the reviewed literature based on 















This chapter presents relevant literature that has been identified, reviewed and 
synthesised. The premise of the literature review is that it should build on what others 
have done instead of potentially re-inventing the wheel. The section begins by focusing 
on a brief review of effective PMTCT, as well as the challenges facing the prevention. 
Various models have been developed to assist with compliance and several of these, 
and their inherent flaws, are discussed in this chapter. This is followed by suggestions in 
literature with regards to interventions to prevent antepartum, intrapartum and 
postpartum HIV transmission for effective PMTCT programme.  
 
2.2 INTERVENTIONS TO PREVENT ANTEPARTUM HIV TRANSMISSION 
 
According to Family Health International (2004:4), a growing body of research and 
experience has identified safe, feasible and effective interventions to reduce MTCT. 
However, for a woman to benefit from these interventions she must come for ANC and 
must access HCT services. 
 
A study conducted by the Public Health Service Task Force (2009:16) in the United 
States of America reveal that initial evaluation of an infected pregnant woman should 
include an assessment of HIV disease status and recommendations regarding ARV 
treatment or alteration of her current ART regimen. The known benefits and potential 
risks of ARV use during pregnancy should be discussed with all women. ART or ARV 
prophylaxis for prevention of perinatal HIV transmission during the antepartum period 
should be recommended to all pregnant, HIV-infected women regardless of plasma HIV 
(Ribonucleic Acid) RNA copy number or CD4 cell count. 
 
The Public Health Service Task Force (2009:16) indicated that AZT should be included 
in the antenatal ARV regimen unless there is severe toxicity or documented resistance. 
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If HIV RNA is detectable, ARV drug resistance studies should be performed before 
starting or modifying therapy. The Public Health Service Task Force (2009:16) advises 
that the importance of adherence to the ARV treatment or prophylaxis regimen should 
be emphasised and coordination of services among prenatal care providers, primary 
care and HIV specialty care providers and public assistance programs should be 
assured as part of recommending antiretroviral drugs during pregnancy.  
 
2.2.1 HIV testing and counselling during antepartum period 
 
Kizito, Woodburn, Kesande, Ameke, Nabulime, Mawanga, Grosskurth and Elliott 
(2008:680) in their study on uptake of HIV and syphilis testing of pregnant women and 
their male partner in PMTCT indicated that the findings showed that HIV testing in 
antepartum period support interventions that address PMTCT, but uptake of opt-in 
testing “where tests are offered, as opposed to opt-out, where they are done routinely” 
is sometimes low in resource-poor settings. This has implications for prevention of 
transmission between serodiscordant partners and for PMTCT programmes adherence.  
 
Kizito et al (2008:680) further stated that the interventions to prevent MTCT are difficult 
for women whose partners are unaware or not supportive of their participation. Thus, 
promoting involvement of male partners in PMTCT programmes may improve uptake, 
behaviour change and compliance with PMTCT measures (Kizito et al 2008:680). 
 
Similarly, Katz, Kiarie, John-Stewart, Richardson, John and Farquhar (2009:6) 
suggested that offering HIV Voluntary Counselling and Testing (HVCT) services for men 
at ANC clinics, with options for couples counselling, may be an acceptable strategy for 
increasing male involvement in HVCT and PMTCT interventions in resource limited 
settings. MTCT remains a significant problem in the developing world despite the 
development and growing availability of effective prevention methods appropriate for 
resource-limited settings (Katz et al 2009:6). 
 
Katz et al (2009:6) study further indicated that HVCT in the context of ANC serves as 
the entry point for targeted PMTCT, although a majority of pregnant women accept 
antenatal HVCT in these settings, many do not learn their HIV serostatus, take part in 
prevention programs or implement interventions to reduce the risk of vertical HIV 
transmission. They advise that male partners play a role not only in women’s risk of 
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acquiring HIV but also in uptake of antenatal HVCT and PMTCT programs (Katz et al. 
2009:6). 
 
In a study by Nyblade and Field-Nguer (2007:37), it was found that community 
acceptance and support address and reduce stigma and discrimination against people 
living with HIV/AIDS, making it psychologically safer for women to participate in HVCT. 
Women faced with a decision about HVCT will be influenced by perceptions of how their 
families and communities will treat them if it becomes known that they participated in 
such a program, in particular if they prove to be HIV positive (Nyblade & Field-Nguer 
2007:37).  
 
Nyblade and Field-Nguer (2007:37) further stated that directors and staff of PMTCT 
programs need to recognise the influence that attitudes of the general community 
toward people living with HIV/AIDS have on women’s participation in HVCT. Therefore 
directors and staff of PMTCT programs should seek to improve community acceptance 
of HVCT and community support of people with HIV/AIDS.  
 
2.2.2 The conceptual model of antepartum interventions 
 
According to Stinson, Myer and Boulle (2008:3), challenges facing effective PMTCT can 
be understood in terms of the theoretical issues of the HAART eligibility initiation model 







Figure 2.1 The HAART eligibility initiation model 
Source: Stinson et al (2008:3) 
 
Stinson et al (2008:3) build on Chopra (2008:19) work with their HAART eligibility 
initiation model of PMTCT. They further indicated that a number of interventions are 
possible to optimise the identification of HIV-infected women early in pregnancy, identify 
those women in need of ART and  start ART rapidly and effectively to promote maternal 
and child health. They indicate that there must be promotion of pre-pregnancy HVCT 
with the interventions that aid pre-pregnancy diagnosis of HIV in all women of 
reproductive age so that women enter antepartum services aware of their serostatus 
and where applicable, already on ARV treatment. 
 
The authors further advised that health facilities should promote awareness of PMTCT 
outside of the ANC setting to ensure that HIV-infected women are aware of the benefits 
of early pregnancy booking before becoming pregnant. They emphasise that health 
facilities should also introduce point of care CD4 count testing to aid fast-tracking of 
clients eligible for HAART. This will alternatively, make provision for all HIV-infected 
women to return for follow-up within a week of booking to get their CD4 results and 
make pregnancy tests free at all services to encourage earlier diagnosis and promote 




2.2.3 Provision of antiretroviral therapy to prevent vertical transmission during 
antepartum period 
 
According to Tsague, Tsiouris, Carter, Mugisha, Tene, Nyankesha, Koblavi-Deme, 
Mugwaneza, Kayirangwa, Sahabo and Abrams (2010:2), MTCT remains the major 
route of paediatric HIV infection. While access to HIV testing during pregnancy has 
improved, most PMTCT programs still rely on administration of single-dose NVP (ds-
NVP) to mothers and babies, a simple, inexpensive, but low efficacy ARV regimen to 
reduce the risk of HIV transmission.  
 
A study by Tsague et al (2010:2) indicated that in November 2009, the WHO issued 
revised guidelines emphasising the use of multi-drug antiretroviral (md-ARV) regimen 
for PMTCT as well as the critical need for measuring antenatal CD4 cell counts to 
determine HAART eligibility. Tsague et al (2010:2) state that the WHO report 
demonstrated that regardless of the model of PMTCT service delivery, it is feasible to 
transition from SD-NVP regimen to more effective md-ARV regimen in a resource 
limited, public sector PMTCT program. However, more efforts are needed to ensure 
effective CD4+ cell count assessment and the enrolment of HIV+ women in ART 
services in stand-alone sites and task-shifting is necessary to ensure the timely initiation 
and follow-up of HAART among pregnant women. 
 
The Royal College of Paediatrics and Child Health (2006:13) agrees with Tsague et al 
(2010:2) by stating that the management of HIV in general has evolved with the use of 
HAART, which has the ability to suppress viral replication. The role of such combination 
treatments in pregnancy is, as yet, unclear and their use does carry a potential risk of 
side effects for both mother and the unborn baby.  
 
McIntyre and Gray (2009:475) share the same view, by advising that to fully implement 
an integrated strategy of providing ART for women with low CD4 _ counts or clinical 
symptoms of AIDS and a prophylactic regimen for other HIV-positive women, the ANC 
services and health workers need to be able to undertake clinical assessment for HIV 
signs and symptoms and obtain a baseline CD4 _ cell count. McIntyre and Gray 
(2009:475) advise that this level of care is not widely available in maternity settings in 
many low-resource settings and needs to be strengthened, along with the infrastructure 




2.3 INTERVENTIONS TO PREVENT INTRAPARTUM HIV TRANSMISSION  
 
According to Rutenberg, Kalibala, Baek and Rosen (2006:49), a substantial proportion 
of perinatal HIV transmission occurs during intrapartum and immediately postpartum. 
This period should be the target of intensive PMTCT program efforts. The efforts should 
include improving obstetrical practices that entails working closely with safe motherhood 
programs to develop and disseminate appropriate guidelines which address HIV and 
PMTCT, skills building and ensuring that health workers have the supplies they need to 
safeguard their clients and themselves.  
 
Study findings by Rutenberg et al (2006:49) indicated that improved obstetrical practice 
interventions to support PMTCT also include reducing unnecessary instrumentation and 
invasive procedures, averting artificial rupture of membranes and prolonged labour, 
reducing unsafe medical practices and improving home-based obstetric practices. 
Rutenberg et al (2006:49) state that good discussion of these practices and suggested 
behaviour change interventions promote good practice. They state that PMTCT 
program should link with programs that screen blood for HIV to ensure that all birthing 
sites have supplies of screened blood for pregnancy-related emergencies. The PMTCT 
program must also work hand-in-hand with safe motherhood efforts to develop policies, 
guidelines, pre-service training and programs which address reducing the risk of HIV 
infection in women and their infants.  
 
The Public Health Service Task Force (2009:59) concurs with Rutenberg et al (2006:49) 
by advising that intrapartum intravenous AZT is recommended for all HIV-infected 
pregnant women, regardless of their antepartum regimen to reduce perinatal HIV 
transmission. For women who are receiving a Stavudine (d4T) -containing antepartum 
regimen, d4T should be discontinued during labour while intravenous AZT is being 
administered. Women who are receiving an antepartum combination ARV treatment 
regimen should continue this regimen on schedule as much as possible during labour 
and prior to scheduled caesarean section.  
 
The Public Health Service Task Force (2009:59) is of the opinion that women receiving 
fixed-dose combination regimens that include AZT should have AZT administered 
intravenously during labour while other ARV components are continued.  For women 
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who have received antepartum ARV drugs but have suboptimal viral suppression near 
delivery, scheduled caesarean delivery is recommended. The Public Health Service 
Task Force (2009:59) states that for women of unknown HIV status who present in 
labour should have rapid HIV antibody testing performed and intravenous AZT initiated 
if the test is positive without waiting for results of the confirmatory test and infant AZT 
should be initiated.  
 
2.3.1 The conceptual model of intrapartum interventions 
 
According to Merchant and Lala (2005:491), challenges facing effective PMTCT can be 
understood in terms of the theoretical issues of the five Phases of PMTCT model as 
displayed in figure 2.2. 
 
 
Figure 2.2 Five phases of PMTCT model 
Source: Merchant and Lala (2005:491) 
 
According to Merchant and Lala (2005:491), as demonstrated in figure 2.3, for the large 
scale implementation of PMTCT, they identified 5 phases, namely: 
 
• Phase 1: This phase of imparting information in the antenatal period on HVCT, 
family planning measures, option of medical termination of pregnancy, 
appropriate infant feeding recommendations, goes a long way in the prevention 
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of unintended pregnancies in HIV-positive women and all women at risk. This 
requires strengthening of family planning services. Women considering 
pregnancy should be encouraged to determine their HIV status and the 
implications of pregnancy when infected with HIV. 
• Phase 2: This consists of ARV prophylaxis to the mother antenatally and 
intranatally and to the baby postnatally. These ARVs act by reducing the viral 
load in the mother and preventing the virus from fixating itself in the child. 
• Phase 3: This phase deals with issues related to replacement feeds versus 
breast feeds in the context of maternal HIV. It supports the mother-infant pair in 
conducting a successful method of feeding. 
• Phase alpha: This phase deals with the primary prevention of HIV through sex 
education, family planning education and avoidance of high risk behaviour. The 
best way to prevent MTCT in girls and women of childbearing age and the 
society at large. 
• Phase omega: This phase deals with support-care protection package to the 
HIV infected mother, child and the family. Issues like pneumocystis jeroveci 
pneumonia prophylaxis, early detection of tuberculosis and management, 
weaning food supplements, vitamin A supplementation are considered. 
 
2.3.2 Provision of prophylactic regimens and cotrimoxazole during intrapartum 
period 
 
According to Homsy, Kalamya, Obonyo, Ojwang, Mugumya, Opio and Mermin 
(2006:149), although combined antenatal, perinatal and neonatal interventions offer 
optimal protection from MTCT, intrapartum regimens such as SD-NVP or AZT/3TC for 
women in labour and their newborns remain the main strategy for the PMTCT in the 
majority of sub-Saharan African countries. Homsy et al (2006:149) indicate that poor 
integration of the strategy in mother and child health (MCH) services has curtailed its 
potential to become the cost effective entry point for comprehensive HIV prevention and 
care. They advise that PMTCT is a multiple-step intervention requiring serial decisions 
and actions on the part of women.  
 
In a study conducted by Adler and Qulo (2007:308), it was found that a short course of 
AZT to pregnant mothers shortly before birth and to the babies after birth reduces 
transmission. In the light of this, the decision of government, if any to deny prospective 
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mother access to AZT on the grounds that it is too expensive and difficult to implement 
is controversial. 
 
McConnell, Bakaki, Eure, Mubiru, Bagenda, Downing, Matovu, Thigpen, Greenberg and 
Fowler (2007:291) share the same view by advising that SD-NVP given to mothers at 
labour and to their newborns has been shown to be effective in reducing MTCT. 
According to McConnell et al (2007:291), SD-NVP low cost, lack of refrigeration 
requirements, availability from donation programs, ability for self-administration has 
made it a first-line mother-to- child transmission prophylaxis regimen in resource-
constrained settings. Not only that, but also need for only simplified health care worker 
training and sustained efficacy at 18 months postpartum in breastfeeding populations, 
relative to other short-course perinatal prophylaxis regimens when other ARV drugs are 
not available or where infrastructure does not allow for more complex regimens.  
 
Prasitwattanaseree, Lallemant, Costagliola, Jourdain and Mary (2006:179) conducted a 
study on influence of mother and infant AZT treatment duration on the age at which HIV 
infection can be detected by PCR in infants, the findings of their study supported 
McConnell et al (2007:291) by advising that perinatal HIV transmission may occur in 
utero and at delivery. In the absence of antiviral prophylaxis, the risk of mother-to-child 
HIV transmission is about 25% and the use of ARV prophylaxis in women during 
pregnancy and in their infants after birth has lowered the risk of transmission. According 
to Prasitwattanaseree et al (2006:179), knowledge of the timing of MTCT is critical to 
better understand the mechanism of protection and important to optimise prevention. 
They caution that timing of transmission cannot be directly observed and detection of 
infection in the child cannot be determined immediately after transmission has occurred, 
but only when infection is established well enough so that biological tests can detect the 
presence of the virus.  
 
Chopra (2008:11) in his study on PMTCT in Africa, operational research to reduce post-
natal and infant mortality concurs with Prasitwattanaseree et al (2006:179) by 
suggesting that short course monotherapy regimes with either AZT from 36 weeks 
gestation, through labour and delivery or NVP given as a single dose to the mother 
during labour and once to the baby reduce transmission at six weeks. Although similar 
results have been observed with dual therapy using AZT and 3TC (AZT/3TC) 
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commencing at 36 weeks gestation, the positive effect seems to be significantly 
reduced after eighteen months of mixed feeding.  
 
Chopra (2008:11) further advises that the WHO currently recommends the ARV 
regimen of AZT from 28 weeks of pregnancy, AZT + 3TC plus SD-NVP at the onset of 
labour, maternal AZT + 3TC for 7 days after delivery and SD-NVP plus one week of 
AZT for newborn infants for PMTCT among women who do not have indications for 
ART for their own health. However in most resource constrained settings it is the short 
course NVP regime that is being used. 
 
2.4 INTERVENTIONS TO PREVENT POSTPARTUM HIV TRANSMISSION 
 
According to the Public Health Service Task Force (2009:72), postpartum period 
provides an opportunity to review and optimise women’s health care and should include 
assessing the need for prophylaxis against opportunistic infections, cervical cancer 
screening and routine immunisations. The Public Health Service Task Force (2009:72) 
indicates that the period also provides an opportunity to assess the need for behavioural 
health interventions which include an assessment for signs of postpartum depression 
and providers should also re-emphasise the importance of safer sex practices. 
 
The Independent Expert Panel (2010:17) indicates that the only method known to 
completely eliminate the risk of breastfeeding-associated HIV transmission is not to 
breastfeed. The Independent Expert Panel (2010:17) advises that this is recommended 
in settings in which infant replacement feeding is affordable and sustainable, clean 
water is widely available, hygiene and sanitation conditions are good and deaths due to 
diarrhoea and other infectious diseases are relatively uncommon. However, this 
approach is neither feasible nor safe in many resource-limited countries because of 
cost, inadequate replacement foods to meet the nutritional needs of the infant, unsafe 
water supply and low acceptability due to stigma associated with not breastfeeding.  
 
The Independent Expert Panel (2010:17) states that exclusive breastfeeding has been 
shown to lower the risk of postnatal HIV transmission compared to mixed feeding, but 
does not eliminate risk. In resource-limited settings, the benefit of breastfeeding in terms 
of reducing infant mortality appears to be greatest in the first 6 months of life. Two 
potential prevention strategies in resource-limited settings are provision of ARV drugs to 
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infants exposed to HIV during breastfeeding and provision of combination ART to 
lactating women. 
 
The Royal College of Paediatrics and Child Health (2006:13) concurs with The 
Independent Expert Panel (2010:17) by advising that for women not infected with HIV, 
breastfeeding is the ideal way to feed infants and should be promoted. However, in HIV 
infected women, breastfeeding will contribute significantly to MTCT. Royal College of 
Paediatrics and Child Health (2006:13) cite example that in the UK, nutritionally 
adequate formula milk alternatives are available and can be obtained on prescription for 
infants of HIV positive mothers. The Royal College of Paediatrics and Child Health 
(2006:13) states that for some women, avoidance of breastfeeding is culturally difficult 
and may be considered a sign to others that the mother is HIV positive. However, there 
is insufficient evidence to change the current recommendation of universal avoidance of 
breastfeeding. 
 
2.4.1 The conceptual model of postpartum interventions 
 
According to MoHSS (2008:29), challenges facing effective PMTCT can be understood 
in terms of the theoretical issues of the diagnosis of HIV infection in children model as 























Figure 2.3 Diagnosis of HIV infection in children 
Source: MoHSS (2010:44) 
 
According to MoHSS (2008:29), as demonstrated in figure 2.4, a large number of HIV-
exposed infants are being identified who require HIV diagnosis and follow-up care. It is 
important to identify young infants with HIV infection early and to refer them for ART 
because of the high mortality from untreated HIV/AIDS. The Ministry is of the opinion 
that promptly identifying young infants, who are not HIV-infected help to reassure their 
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parents, discharge them from costly follow-up and measure the overall effectiveness of 
the PMTCT programme.  
 
According to MoHSS (2010:45), challenges facing effective PMTCT can be understood 





Figure 2.4 HIV antibody testing 
Source: MoHSS (2010:45) 
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According to MoHSS (2010:45), as demonstrated in figure 2.4, HIV antibody testing 
gives definitive results for diagnosis of HIV infection in children less than18 months old. 
Either rapid HIV testing or enzyme-linked immuno sorbent assay (ELISA) can be used. 
As such this is the recommended testing approach for the diagnosis or exclusion of HIV 
in this age group. The MoHSS states that antibody testing for HIV diagnosis is less 
useful in infants because passively transferred maternal anti-HIV antibodies may persist 
and be detected in a child for up to 18 months of age. The MoHSS (2010:45) states that 
following HIV antibody testing at 9 months of age or older, diagnosis of HIV infection 
may be excluded if the child’s test is negative and there has been no breastfeeding for 
the past 3 months. If the child tests positive before 18 months, an HIV DNA PCR test 
should be performed to confirm HIV infection. 
 
2.4.2 Safe feeding practices for the infant 
 
Saadeh, Henderson and Vallenas (2005:8) define replacement feeding as feeding an 
infant receiving no breast milk a diet that provides the necessary nutrients and suitable 
breast milk substitutes include commercial infant formula or home modified animal-milk. 
They indicate that little is known about how replacement feeding affects infant morbidity 
or mortality in the context of PMTCT programmes. According to Saadeh et al (2005:8), 
the indications are that mortality is high for both uninfected and infected infants of HIV-
positive mothers and avoidance of all breastfeeding is recommended for HIV-positive 
mothers when replacement feeding is acceptable, feasible, affordable, sustainable and 
safe. Otherwise, exclusive breastfeeding for the first months of life is recommended.  
 
Saadeh et al (2005:8) define exclusive breastfeeding as nourishing an infant on breast 
milk alone with no other liquids or solid foods apart from human milk, although 
prescribed medicines and vitamin-mineral supplements are allowed within this 
definition. Saadeh et al (2005:8) advise that while early cessation means completely 
stopping breastfeeding before age 2 years and ideally, it occurs among HIV-positive 
mothers as soon as replacement feeding is acceptable, feasible, affordable, sustainable 
and safe, as a strategy to reduce the risk of MTCT by limiting the infant’s exposure to 
HIV infection through breast milk.  
 
Kuhn, Aldrovandi, Sinkala, Kankasa, Semrau, Mwiya, Kasonde, Scott, Vwalika, Walter, 
Bulterys, Wei-Yann Tsai and Thea (2008:131) in their study on effects of early abrupt 
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weaning on HIV-free survival of children, their findings concur with Saadeh et al 
(2005:8) by explaining that breast-feeding poses a dilemma for women who live in low-
resource settings and who are infected with HIV because the practice can transmit HIV 
but is the source of optimal nutrition and protection against other serious infectious 
diseases. The authors advised that early cessation of breastfeeding has been 
recommended to balance these competing risks favourably – reducing postnatal 
transmission of HIV while preserving the nutritional and immunologic benefits of 
breastfeeding at the time when they are needed most.  
 
Kuhn et al (2008:131) indicate that exclusive breast-feeding confers lower risks of 
postnatal transmission of HIV than predominant or partial breastfeeding but is 
recommended only for 6 months, after which infants require other foods to complement 
breast milk. If early weaning is to be encouraged for HIV-infected women, the end of 
exclusive breast-feeding offers a logical end point. The authors further indicated that in 
low-resource settings, many programs that attempt to prevent MTCT have 
recommended abrupt or rapid weaning to minimise the period of nonexclusive 
breastfeeding. 
 
Desmond, Bland, Boyce, Coovadia, Coutsoudis, Rollins and Newell (2008:1) support 
Kuhn et al (2008:131) by advising that exclusive breast milk is endorsed by the WHO as 
the ideal food for infants from birth to six months, because of its nutritional superiority 
over commercial formulas, and the significant protection afforded to the infant against 
acute and chronic illnesses. The authors stated that exclusive breastfeeding by HIV-
infected women has recently been shown to carry less risk of postnatal HIV 
transmission compared to mixed feeding, particularly with solid foods and has been 
associated with greater HIV-free survival at 18 months compared to infants fed solely on 
formula milk. They further advise that there is no doubt; therefore, that exclusive 
breastfeeding for the first six months should be promoted globally and exclusive 
breastfeeding for six months is feasible and practical, as demonstrated in many 
settings, including high HIV prevalence areas (Desmond et al 2008:1; Kuhn et al 
2008:131). 
  
Kuhn, Sinkala, Kankasa, Semrau, Kasonde, Scott, Mwiya, Vwalika, Walter, Tsai, 
Aldrovandi and Thea (2007:1) in their study on high uptake of exclusive breastfeeding 
and reduced early post-natal HIV transmission, their findings concur with Desmond et al 
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(2008:1) by indicating that promotion of exclusive breastfeeding has been a cornerstone 
of public health measures to promote child survival. Exclusive breastfeeding is 
associated with lower risks of diarrhoea and pneumonia-related infant morbidity and 
mortality than breastfeeding with addition of other fluids and solids in both developed 
and developing world settings (Desmond et al 2008:1).  
 
2.4.3 Infant rapid initiation of antiretroviral treatment 
 
According to th MoHSS (2008:7), women who have not been tested during pregnancy 
or labour should receive counselling and be offered rapid HIV testing in the immediate 
postpartum period. If the mother is found to be HIV positive, the newborn can be started 
immediately on ARV prophylaxis. The MoHSS advises that within the prescribed 72 
hours after delivery, there is still a window of opportunity to offer PMTCT interventions 
that include ARV prophylaxis to the baby and counselling on safe infant feeding options. 
 
Findings from a study conducted by UNICEF (2007:4) revealed that following all 
complex steps does not yet guarantee that the infant is not infected with HIV. 
Addressing properly infant feeding options is as important as applying ARV prophylaxis. 
Around one third of all infections transmitted from the mother to the baby may occur 
through breastfeeding and WHO recommends avoiding breastfeeding from birth only if 
substitute feeding is acceptable, feasible, affordable, sustainable and safe. According to 
UNICEF (2007:4), exclusive breastfeeding is supported in all other cases when these 
conditions are not met and WHO recommends that all infants exposed to HIV should 
receive cotrimoxazole prophylaxis starting at 4-6 weeks of age and continuing until HIV 
infection is excluded.  
 
UNICEF (2007:4) stated that cotrimoxazole reduce child mortality in HIV positive 
children by over 40%, however, although cotrimoxazole is widely available and is 
affordable, the progress of its provision for prophylaxis in infants exposed to HIV and 
HIV positive mothers is still slow. To measure the effectiveness of the PMTCT 
intervention and be able to offer proper care, the infant needs to be diagnosed as early 
as possible. UNICEF (2007:4) further advises that the testing method that detects 
antibodies used to test adults cannot be applied in children younger than 18 months due 
to the presence of antibodies from the mother in the infant’s blood. Instead, virology 
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testing is required using the PCR method, which is the gold standard of Early Infant 
Diagnosis (EID). 
 
Public Health Service Task Force (2009:76) agrees with UNICEF (2007:4) by advising 
that all HIV-exposed infants should receive postpartum ARV drugs to reduce perinatal 
HIV transmission. The 6-week neonatal AZT chemoprophylaxis regimen is 
recommended for all HIV-exposed infants. They advise that infants born to mothers who 
have received standard antepartum and intrapartum antiretroviral prophylaxis and have 
undetectable viral load are at very low risk of HIV transmission. According to the Public 
Health Service Task Force (2009:76), the risk of transmission is increased when the 
mother has high viral load at delivery or when the mother has not received the full 
antepartum and intrapartum prophylaxis regimen.  
 
The Public Health Service Task Force (2009:77) states that infants born to women who 
received standard ARV prophylaxis regimens during pregnancy and labour and had 
undetectable viral load at delivery or born to mothers with low viral load at delivery and 
delivered by cesarean section have a very small risk of HIV acquisition. Such infants 
should receive the 6-week AZT infant prophylaxis regimen.  
 
Similarly, Betancourt, Abrams, McBain and Fawzi (2010:1) in their study on family-
centred approach to PMCTC indicated that many programmes that aim to prevent 
mother-to-child transmission of HIV in resource-limited settings have tended to take a 
narrow focus, often providing targeted biomedical interventions during late pregnancy 
and delivery, and neglecting the impact of HIV on the health of both pregnant women 
and families. Betancourt et al (2010:1) indicate that the narrow focus of PMTCT to date 
represents a lost opportunity to effectively combat the vertical transmission of HIV to 
children – a largely preventable infection given current scientific knowledge.  
 
Betancourt et al (2010:1) are of the opinion that family-focused approaches facilitate 
broader implementation of PMTCT programming, addressing the comprehensive needs 
of women, particularly those in need of treatment for their own health, as well as of 
children and other family members, over time. Betancourt et al (2010:1) advise that a 
paradigm shift is needed in PMTCT which considers the needs of entire families, rather 
than placing a singular focus on preventing MTCT during pregnancy and delivery.  
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Betancourt et al (2010:1) advise that PMTCT represents an entry point for improving 
overall family health. 
 
2.5  CONCLUSION 
 
A review of the literature has depicted areas of effective PMTCT and discussed PMTCT 
interventions based on three concepts, antepartum, intrapartum and postpartum 
interventions. Literature review indicate that promoting involvement of male partners in 
PMTCT programmes, providing the couple counselling and testing, antiretroviral drugs 
availability, caesarean intervention, administering SD-NVP, giving HIV infected mothers 
HAART during the breast-feeding period and women education about exclusive 
breastfeeding prior to delivery are some of interventions in the PMTCT.  In this chapter, 
different PMTCT management models have also been highlighted. These models were 
developed by some interested management experts and most of the models share 
similar principles. Chapter 3 will describe and discuss the details of the research 
























This chapter focuses on the research design and method applied to resolve the main 
and sub-problems as identified in chapter one. It includes an outline of the research 
methodology adopted for this study, that is, the research design together with the 
reason why the study was conducted (purpose) and the objectives of the study. 
Population and sampling rationale are explained, as well as the setting under which the 
study was undertaken. Data collection method, process and analysis are also 
discussed. Lastly, details pertaining to issues of reliability, validity and ethical 
considerations are also explained. 
 
3.2 RESEARCH DESIGN  
 
Crosby et al (2006:75) defined research design as “the strategy the investigator 
chooses for answering the research question”. The research question to be answered 
determined and helped the researcher identify the most appropriate research design 
used. The design used for this study was a descriptive cross-sectional design. 
 
3.2.1 Study area 
 
This research was conducted in Oshakati District Health Centre, a health Centre in 
Oshana health region. Oshakati district health centre is located in Oshakati, which is the 
second biggest town in Namibia. The health centre is on the same ground with Oshakati 
intermediate referral hospital.  
 
3.2.2 Research design 
 
A descriptive quantitative cross-sectional survey was conducted among 2 groups of 
participants, i.e. patients and nurses at Oshakati District Health Centre. Descriptive 
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study allow researcher to describe phenomena as they occurred and to measure 
variables quantitatively (Brink 2009:104). The design is best suit to describe challenges 
affecting effective prevention of mother-to-child transmission of HIV infection at 
Oshakati District Health Centre. 
 




The population refer to the entire group or objects of interest to the researcher (Bless & 
Higson-Smith 1995:85). In this study the population were all HCWs experienced in 
PMTCT and patients who attended ANC and post natal care services at Oshakati 
District health Centre. In the context of this study,” HCWs experienced” is defined as 
HCWs who worked in the ANC/PMTCT unit. The patient and HCWs participants that 
formed the study population have experiences of Oshakati District Health Centre’s 
antepartum, intrapartum and postpartum HIV transmission prevention interventions. The 
accessible population were a sample of patients who attended ANC and post natal care 
services during the survey period and met the inclusion criteria. The accessible 
population of HCWs were all HCWs who were on duty at Oshakati District Heal Centre 
during the survey period. 
 
3.3.2 Sampling methods 
 
The sampling method chosen for this study was purposive sampling. Leedy and Ormrod 
(2010:211) indicate that purposive samples are samples where subjects of the study are 
selected with a specific purpose in mind, such as the likelihood of representing best 
practice in a particular issue. The composition of such a sample is not made with the 
aim of it being statistically representative of the population. Such samples comprise 
individuals considered to have the knowledge and information in order to provide useful 
ideas, experiences and insights Leedy and Ormrod (2010:211). Therefore, the sample 
for this study was purposely emanating from all HCWs experienced in PMTCT and 
patients who attended ANC and post natal care services at Oshakati District health 




Criteria of inclusion, or eligibility criteria as Brink (2006:133) refers to them, are those 
specific characteristics which make elements of the population eligible for selection to 
participate in a study. This study included all HCWs working at Oshakati District Health 
Centre experienced in PMTCT and patients who attended ANC and post natal care 
services at Oshakati district health Centre during one week of the research survey 
because they had experience of Oshakati District Health Centre’s antepartum, 
intrapartum  and postpartum HIV transmission prevention interventions services. 
 
Polit and Beck (2006:499) define exclusion criteria as those specific characteristics that 
certain elements in the population do not possess and are therefore not eligible for 
inclusion in a sample. In this study, HCWs not experienced in PMTCT were not 
surveyed.  Also excluded were women who did not attend ANC and post natal care 
services, or those under 18 years of age. 
 
The final sample surveyed comprised of both male and female HCWs experienced in 
PMTCT and women who attended ANC and post natal care services at Oshakati District 
health Centre during one week of the research survey, but there was also one male 
patient who accompanied the partner. A total of 160 participants have participated in the 
survey, and this sample included 30 HCWs and 130 patients. 
 
3.3.3 Data collection methods 
 
Structured questionnaires: A self-administered structured questionnaire was issued to 
participants to respond to. This was in line with Shajahan (2005:133) suggestion that 
questionnaires are widely used for data collection in social science research, particularly 
in surveys. It is a fairly reliable tool for gathering data from large, diverse, varied and 
scattered social groups. It is used in obtaining objective and quantitative data as well as 
in gathering information of a qualitative nature (Shajahan 2005:133). 
 
For the purpose of this study two different structured data collection tools were used, 
one for the HCWs and another for patients. This was necessary to get the patients and 
HCWs’ perception on challenges affecting effecting PMTCT at Oshakati District Health 




The questionnaires consisted of four main (4) questions and each questionnaire 
consisted of sections A and B. Section A for both HCWs and patient participants 
collected the socio-demographic data such as age, gender and population group.  But 
the HCWs’ questionnaire collected additional data under section A, i.e level of education 
and years of experience. Section B required participants both HCWs and patients  to 
rate their perception towards the extent to which Oshakati District Health Centre’s 
antepartum, intrapartum and postpartum HIV transmission prevention interventions 
programmes effectively contribute to the PMTCT of HIV infection (refer to Annexures A 
and B).  
 
Close-ended questions in form of statements were used and participants were 
requested to respond to those statements, indicating how they agreed to the statements 
by use of a 5 type Likert scale. The scale included, strongly disagree, disagree, 
uncertain, agree and strongly agree. The statements were about interventions for 
prevention of mother-to-child transmission during antepartum, intrapartum and 
postpartum period. This was in line with Polit and Beck (2006:498) guideline that data 
collection is the gathering of information to address a research problem. 
 
The questionnaires contained questions of close-ended and a 5-point Likert scale was 
used. This was in line with Hofstee (2006:134) suggestions that the Likert scale is a 
widely used means for measuring perceptions. Respondents indicated how they agree 
or disagree with statements.   
 
Hofstee (2006:133) assert that the aim of the questionnaire is to gather information 
specific information about a particular subject of research. The researcher ensured that 
the information gathered had some tolerable accuracy and completeness by depicting 
all questions from literature review in chapter 2. As is common in research, pre-testing 
of the instrument was conducted on four participants (two staff participants and two 
patients’ participants) in order to comply with Polit and Beck (2006:41) advice that pre-
testing is done by administering the questionnaire to a small but representative sample 
of potential participants under conditions that are identical in all respects to those under 
which the final questionnaire will be administered. 
 
Pre-testing of the nurses and patients questionnaires, led to the changes in the 
questionnaire to include more closed ended questions with a Likert scale then just open 
 
36 
ended questions. The pre-testing also informs the researcher of the need to translate 
the patient questionnaire into an African language known as “Oshiwambo” language as 
per recommendations of patients and HCWs who participated in the pre-testing of 
instruments (Annexure C). Additional item were added to the questionnaire as a result 
of pre-testing that included adding an age group of less than 20 years. Patients who 
participated in the pre-testing also recommended that distributing the questionnaire in 
the waiting area was best than on exit, when their focus is just to go back home. 
 
A week prior data collection research briefing was done with the nurse-in-charge of 
antenatal and postnatal units informing them of intention to start with data collection. 
Nurses in charge were briefed about the research project, purpose and the data 
collection method who subsequently briefed their nurses experienced in PMTCT and 
women who attended ANC and post natal care services at Oshakati District Health 
Centre during one week of the research survey. This briefing was very crucial in making 
sure that no service interruption or no adverse reaction as result of the survey. Self-
administered questionnaire were distributed to the HCWs, one-by-one. Questionnaires 
for patients in a language of their choice, English or Oshiwambo were distributed every 
day while patients were in the waiting areas and they were asked to drop them off 
anytime they finish. 
 
3.3.4 Data analysis 
 
The research results were analysed by the researcher, using the Microsoft Excel 
program 2007 version. Statistical arithmetic mean and frequency were used to 
determine percentages and the information was presented in tables and graphical 
formats. This was in line with Polit and Beck (2006:498) advice that the analysis of data 
is one of the most important aspects of research. Although a 5-point Likert scale was 
used to respond to statements on PMTCT interventions, under analysis, the researcher 
analysed strongly agree and agree as “agree” while strongly disagree and disagree 
were analysed “disagree” and lastly “uncertain”. 
 
3.4 VALIDITY AND RELIABILITY 
 
Leedy and Ormrod (2010:31) suggest that the internal and external validity of the 
researcher’s measurement instruments influence the extent to which one can learn 
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something about the phenomenon being studied, the probability that statistical 
significance will be obtained in the data analysis and the extent to which the researcher 
can draw meaningful conclusions from the data.  
 
This study made use of content and construct validity where the implemented 
measurement instrument, being the questionnaires, required feedback from participants 
based on their perceptions. The content of the questionnaires required specific 
feedback on effective PMTCT from HCWs experienced in PMTCT and women who 
attended ANC and post natal care services at Oshakati District health Centre during one 
week of the research survey. 
 
Whitehead and Mcniff (2006:97) define validity as the degree to which an instrument (in 
this case the questionnaires) actually measures what it is intended to measure. 
Whitehead and Mcniff (2006:97) posit that the measurement instruments provide a 
basis on which the entire research effort rests. They have further identified several 
types of validity: 
 
Face validity is the extent to which, on the surface, an instrument looks like it’s 
measuring a particular characteristic and is often useful for ensuring the co-operation of 
people who are participating in a research study (Mcniff 2006:97). The researcher had a 
face-to-face interaction with nurses in charge of antenatal and postnatal units for 
detailed explanation on the purpose of the survey that assisted in achieving face 
validity. 
 
Content validity refers to the extent to which a measurement instrument is a 
representative sample of the content area being measured. It is often a consideration 
when people’s achievement in some area is to be assessed (Mcniff 2006:97). The 
researcher ensured that the questions covered all the important areas on PMTCT 
interventions identified in the literature review in order to address content validity. 
 
Criterion validity refers to the extent to which the results of an assessment instrument 
correlate to one another (Mcniff 2006:97). As already stated the participants that formed 
the study population had experiences of Oshakati District Health Centre’s antepartum, 





Construct validity refers to the extent to which an instrument measures a 
characteristic that cannot be directly observed but must instead be inferred from 
patterns in people’s behaviour (Mcniff 2006:97). This was addressed by the quantitative 
survey. The researcher ensured that the constructs were clear, unambiguous and did 
not result in bias. 
 
3.5  ETHICAL CONSIDERATIONS  
 
In research one has to conform to ethical standards. In this study self-administered 
questionnaires were given to participants. Therefore it was important for the researcher 
to conform to ethical standards, to get permission, obtain consent, and protect the right 
of the institution as well as the rights of participants. 
 
3.5.1 Protecting the rights of the participants 
 
Informed consent: Informed written consent was obtained from nurses and patients 
who participated in the study, prior to accepting a questionnaire (Annexure H). Patient 
who were less than 18 years were excluded from the study. 
 
Autonomy: Prior to receiving the self-administered questionnaire, the researcher 
explained to participants individually, that participation is voluntary and that participants 
have the right to terminate participation at anytime they deem necessary. 
 
Confidentiality and privacy: In this study the researcher upheld privacy and 
confidentiality of the participants, by consulting participants one-by-one to explain the 
purpose of the study and to obtain consent and hand-over the questionnaire. The 
researcher did not collect any information that might expose the identity of participants 
and in addition, no names were used.  
 
Justice: The researcher explained consent to all the participants to make sure that all 
participants understood what was the purpose of the study for them to make informed 




Coercion and perverse incentives: There were no undue incentives to those who 
consented to form part of the study and respondents were neither intimidated nor 
compelled to take part in the study. 
 
Deception: In this research, efforts were made to ensure that participants were not 
deceived in any way during the process. In this study, the research explained to the 
participants the purpose of the study and the informed them of their rights with regard to 
participation, and that they can stop participation anytime. The researcher translated the 
patient questionnaire in a local African language called "Oshiwambo" a language 
spoken by most patients in the catchment area of Oshakati District. This ensured 
patients who do not speak nor understand English equally take part and understand 
what is being asked and they can give their opinion. 
 
3.5.2 Protecting the right of the institution 
 
The study conformed to all ethical considerations consistent to conducting a study.  
Ethical clearance was ensured; permission was sought and granted by the Ethics 
Committee of the University of South Africa (Annexure D), Ministry of Health and Social 
Services (Annexure E), Oshana Regional Directorate of Health (Annexure F). In 
carrying out this research, ethical issues were also considered by seeking consent from 
participants through a detailed explanation on the purpose of the survey and by 
providing full assurance to the participants of anonymity and confidentiality as referred 
to in the consent forms (Annexures G and H) that were affixed to the questionnaires. 
The Oshana Health Region and the study supervisor were both informed of the changes 
in the questionnaires and approach after pre-testing.  
 
3.5.3 Scientific integrity 
 
All sources consulted were acknowledged, cited and reference according to the 





3.6  CONCLUSION 
 
This chapter highlighted the research method used in this study. Research design 
followed in this study was also explained. Outlined in the methodology were the study 
area; sampling procedure followed; including the eligibility criteria, sample size and 
characteristics. Data collection processes were explained also highlighting the ethical 
considerations involved. Data analysis process was looked into. Measures to ensure 
reliability and validity were addressed. The next chapter will focus on the presentation 













This chapter presents the analysis of the research findings as well as the interpretation 
and discussion of the findings. Results are presented in tables followed by the 
discussion of such results. In this chapter primary data findings from staff challenges in 
PMTCT and women who attended ANC and post natal care services at Oshakati District 
health Centre during one week of the research survey have been examined, analysed 
and findings have been linked to theories.  
 
4.2 DATA MANAGEMENT AND ANALYSIS  
 
4.2.1  Data quality assurance  
 
The researcher checked all completed data collection instrument for completeness and 
consistency before being entered into computer.  
 
4.2.2 Data entry  
 
The raw data on data collection instrument was coded and entered into computer by a 
researcher using the Microsoft Excel program. 
  
4.2.3 Data cleaning  
 
The researcher had worked in ensuring that data was accurately captured and cleaned 
using the Microsoft Excel program (XP 2007 version). All inconsistent data entries were 





4.2.4 Data processing and analysis  
 
Data from the Microsoft Excel 2007 program were used to draw statistics using 
frequency distribution and percentages and these were displayed using tables. 
 
4.3 RESEARCH RESULTS  
 
4.3.1 Demographic data of the study participants 
 
This sections contained participants’ demographic data. For, patients and healthcare 
workers’ gender, age, population group is reported. Level of education and years of 
experience were reported for health care workers (HCWs) only. 
 
4.3.1.1 Gender distribution 
 
Table 4.1 illustrates the results obtained from the analysis of participants’ gender 
distribution. The results of HCWs indicate that 26 (86.67%) were females whiles 4 
(13.33%) were males.  The results of patients’ responses indicate that the majority 
(99.23%) were females and only 1 (0.77%) were males. Based on the findings, the 
majority of participants in this survey were females. 
 
Table 4.1 Participants’ gender distribution (n=160) 
 
Gender  HCWs Patients Frequency Percent Frequency Percent 
Male 4 13.33 1 0.77 
Female 26 86.67 129 99.23 
Total 30 100.00 130 100.00 
 
4.3.1.2 Population group  
 
Table 4.2 shows the results of the distribution of participants’ population group. The 
results of HCWs indicate that the majority 28 (93.33) were black, 1 (3.33%) were 
coloured and the remaining 1 (3.33%) did not disclose their population group. The 
results of patients’ population group distribution showed that the majority (98.46%) were 
black, while equal proportions 1 (0.77%) were coloured and those who did not disclose 
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1 (0.77%). Based on the research findings, most of the participants were from the black 
population group.  
 
Table 4.2 Participants’ population group (n=160) 
 
Participants Population group Frequency Percent 
HCWs Black 28 93.33 
Coloured 1 3.33 
Did not disclose 1  3.33 
Total 30 100.00 
Participants Population group Frequency Percent 
Patients Black 128 98.46 
Coloured 1 0.77 
Did not disclose 1 0.77 
Total 130 100.00 
 
4.3.1.3 Age group of participants  
 
4. 3.1.3.1 Age group distribution for HCWs 
 
Figure 4.1 illustrates the results obtained for participants’ age group profile. The results 
of HCWs showed that 12 (40%) were between the age group of 31-40 years, 11 
(36.67%) were between 20-30 years, and 5 (16.67%) were 51 years and above. Only 2 
(6.67%) were between 41-50 years. Based on the research findings, most HCWs 






Figure 4.1 Distribution of age group for HCWs (n=30) 
 
 
4.3.1.3.2 Age group distribution for patients 
 
As shown in figure 4.2 age group distribution for patients revealed that slightly above 
half (53.08%) of the participants were between 20-30 years, 32 (24.62%) were between 
31-40 years and 19 (14.62%) were under the age of 20 years. Only 10 (7.69%) were 
between the ages of 41-50 years. Based on the research findings, most patients who 




















Figure 4.2 Distribution of age group for patients (n=130) 
 
4.3.1.4 HCWs years of experience 
 
Table 4.3 illustrates the analysis of HCWs’ years of working experience and the results 
showed that 12 (40%) indicated that they have between 1-5 years of working 
experience, 8(26.67%) have less than 1 year and 7 (23.33%) have between 6-10 years. 
Only a small proportion (6.67%) reported over 15 years while 1 (3.33%) indicated a 
working experience between 11-15 years. Based on the research findings, most HCWs 





















Table 4.3 HCWs’ years of experience (n=30) 
 
Years of experience Frequency Percent  
Less than 1 Year 8 26.67 
1-5 Years 12 40.00 
6-10 Years 7 23.33 
11-15 Years 1 3.33 
Over 15 Years 2  6.67 
Total 30 100.00 
 
4.3.1.5 Level of highest education for HCWs 
 
Figure 4.3 indicates that HCWs’ who participated in this survey have achieved the 
following level of education: below Matric represents 1 (3.33%), Matric represents 2 
(6.67%), Certificate represents 15 (50%), Diploma represents 9 (30%), Undergraduate 
degree represents 1 (3.33%), Honours/B Tech represents 1 (3.33%). This finding 
suggests that 90% of the participants have received formal education and have 

























4.3.2 Interventions to effective prevention of antepartum HIV transmission 
 
Table 4.4 HCWs’ responses on interventions to effective prevention of 
antepartum HIV transmission (n=30) 
 
In table 4.4, the researcher analysed strongly agree and agree as “agree” while strongly 
disagree and disagree were analysed “disagree” and lastly “uncertain”. 
 
CHARACTERISTICS Frequency Percent  
Most women come for antepartum care and access HIV counselling 
and testing services. 
  
Agreed 29 96.67 
Disagreed 1 3.33 
Uncertain 0 0.00 
Total 30 100.00 
The importance of adherence to the antiretroviral treatment during 
pregnancy is emphasised. 
  
Agreed 27 90.00 
Disagreed 2 7.00 
Uncertain 1 3.00 
Total 30 100.00 
There is male partners’ involvement in prevention of mother-to child 
transmission of HIV infection programme. 
  
Agreed 15 50.00 
Disagreed 8 27.00 
Uncertain 7 23.00 
Total 30 100.00 
There is couple HIV counselling and testing that increase acceptance 
of testing by pregnant women. 
  
Agreed 17 56.67 
Disagreed 5 16.67 
Uncertain 8 26.67 
Total 30 100.00 
HIV testing and counselling is provided to all pregnant women as a 
routine comprehensive package of care. 
  
Agreed 30 100.00 
Disagreed 0 0.00 
Uncertain 0 0.00 
Total 30 100.00 
Enzyme-Linked Immunosorbent Assay is used in prevention of 
mother-to child transmission of HIV infection. 
  
Agreed 9 30.00 
Disagreed 10 33.33 
Uncertain 11 36.67 




CHARACTERISTICS Frequency Percent  
Management of HIV in women evolve the use of highly active 
antiretroviral therapy. 
  
Agreed 25 83.33 
Disagreed 3 10.00 
Uncertain 2 6.67 
Total 30 100.00 
The antenatal services undertake clinical assessment for HIV signs 
and symptoms and obtain a baseline CD4 _ cell count. 
  
Agreed 27 90.00 
Disagreed 2 6.67 
Uncertain 1 3.33 
Total 30 100.00 
 
As shown in table 4.4, the results of the survey indicated that 29 (96.67%) of HCWs 
agreed that most women come for antepartum care and access HIV counselling and 
testing services while 1 (3.33%) disagreed with the statement. The research findings 
mean that women do attend ANC and access HCT services. A study conducted by the 
Family Health International (2004:4) reveals that a growing body of research and 
experience has identified safe, feasible and effective interventions to reduce HIV 
transmission from HIV-infected pregnant women to their infants. However, for a woman 
to benefit from these interventions she must come for ANC and must access HCT 
services. 
 
A total of 27 (90.00%) of HCWs who participated in this survey agreed that the 
importance of adherence to the antiretroviral treatment during pregnancy is 
emphasised, compared to 2 (7.00%) of HCWs who disagreed with the statement while 1 
(3.00%) of HCW were uncertain. The findings can be compared with the findings of study 
conducted by the Public Health Service Task Force (2009:16) that reveal that the 
importance of adherence to the antiretroviral treatment or prophylaxis regimen should 
be emphasised and coordination of services among prenatal care providers, primary 
care and HIV specialty care providers and public assistance programs should be 
assured as part of recommending antiretroviral drugs during pregnancy. ‘ 
 
The result further indicated that, 15 (50.0%) HCWs who participated in this survey 
agreed that male partners are involved in PMTCT of HIV intervention programme 
compared to 8 (27.0%) of HCWs who disagreed with the statement while 7 (23.0%) of 
HCW were uncertain. This finding indicates that male partners are involved in PMTCT. 
Interventions are difficult for women whose partners are unaware or not supportive of 
 
49 
their participation. Thus, promoting involvement of male partners in prevention of 
mother-to child transmission of HIV infection programmes may improve uptake, 
behaviour change and compliance with prevention of mother-to child transmission of 
HIV infection measures (Kizito et al 2008:680). HCWs were asked if there is male 
partners’ involvement in PMTCT of HIV intervention programme.  
 
With respect to couple HIV counselling and testing that increase acceptance of testing 
by pregnant women, results have shown that 17 (56.67%) of HCWs agreed that there is 
couple HIV counselling and testing that increase acceptance of testing by pregnant 
women, 5 (16.67%) disagreed while 8 (26.67%) were uncertain. This finding can be 
compared with the findings of study conducted by The Independent Expert Panel 
(2010:9) that revealed that provision of couple counselling and testing has been shown 
to increase acceptance of HIV testing by pregnant women. High uptake of testing can 
be achieved with routine PITC combined with use of rapid tests offering same day 
results in antenatal and delivery settings.  
 
Routine HCT is the cornerstone of all interventions to reduce MTCT. All HCWs 30 
(100%) agreed that HIV testing and counselling is provided to all pregnant women as a 
routine comprehensive package of care. This finding means that there is effective HIV 
testing and counselling provided to all pregnant women. In the PMTCT programme, pre-
test, post-test and on-going counselling should be offered to all pregnant women, 
postpartum women, their partners and families. Therefore, HCT in the ANC clinic should 
be provided to all pregnant women as part of a routine comprehensive package of care 
(MoHSS 2008:6).  
 
The result in table 4.4 illustrated that 9 (30.0%) of the HCWS agreed that ELISA is used 
in PMTCT of HIV infection, 10 (33.3%) disagreed with the statement and 11 (36.7%) 
were uncertain. This finding indicates that there are challenges with the use of ELISA in 
PMTCT. While tests commonly used for HIV diagnosis are ELISA and Rapid HIV Test. 
ELISA is highly sensitive and is widely used in PMTCT and HVCT before the 
introduction of rapid testing but it requires more expensive infrastructure, trained 
personnel and batch testing (MoHSS 2008:7).  
 
This study results as tabulated in table 4.4 indicated that the majority of HCWs (83.3%) 
agreed that management of HIV among women evolve the use of HAART, 3 (10.0%) of 
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the HCWs disagreed with this statement and 2 (6.67%) were uncertain. The findings 
indicate that management of HIV among women evolve the use of HAART. The 
management of HIV in general has evolved with the use of HAART, which has the 
ability to suppress viral replication (Royal College of Paediatrics and Child Health 
2006:13).  
 
An overwhelming majority of the surveyed HCWs (90.00%) agreed that antenatal 
services undertake clinical assessment for HIV signs and symptoms and obtain a 
baseline CD4 _ cell count, whiles a small proportion (6.67%) disagreed with the 
statement and 1(3.33%) were uncertain. The results indicate that antenatal services 
undertake clinical assessment for HIV signs and symptoms. In order to fully implement 
an integrated strategy for providing ART for pregnant women with a low CD4 _ counts 
or clinical symptoms of AIDS and a prophylactic regimen for other HIV-positive women, 
the antenatal services and health workers need to be able to undertake clinical 
assessment for HIV signs and symptoms and obtain a baseline CD4 _ cell count 
(McIntyre & Gray 2009:475).  
 
 
Table 4.5 Patients’ responses on interventions to effective prevention of 




Frequency  Percent  
There is presence of high quality voluntary counselling and testing 
service. 
  
Agreed 112 86.15 
Disagreed 6 4.62 
Uncertain 12 9.23 
Total 130 100.00 
There is integration of highly active antiretroviral therapy services 
prioritised in antenatal services. 
  
Agreed 79 60.77 
Disagreed 21 16.15 
Uncertain 30 23.08 
Total 130 100.00 
There is community acceptance of HIV voluntary counselling, 
testing. 
  
Agreed 103 79.23 
Disagreed 14 10.77 
Uncertain 13 10.00 





Frequency  Percent  
Rapid HIV test is the first choice for routine testing.   
Agreed 115 88.46 
Disagreed 9 6.92 
Uncertain 6 4.62 
Total 130 100.00 
They use md-ARV for prevention of mother-to child transmission of 
HIV infection. 
  
Agreed 101 77.69 
Disagreed 12 9.23 
Uncertain 17 13.08 
Total 130 100.00 
HIV-infected pregnant women are counselled regarding the benefits 
of antiretroviral therapy for prevention of perinatal transmission. 
  
Agreed 115 88.46 
Disagreed 5 3.85 
Uncertain 10 7.69 
Total 130 100.00 
Antiretroviral drugs are always available for interventions in 
reduction of HIV infection transmission. 
  
Agreed 106 81.54 
Disagreed 9 6.92 
Uncertain 15 11.54 
Total 130 100.00 
 
The results in table 4.5 indicate that 112 (86.5%) of the patients agreed that there is 
presence of high quality voluntary counselling and testing service, 6 (4.6%) disagreed 
with the statement while 12 (9.2%) were uncertain. The results mean that there is high 
quality voluntary counselling. The key critical activities that need to happen in order to 
achieve the overall aim of reduced HIV incidence includes the presence of high quality 
HVCT service, regular supplies, increased community and individual knowledge and 
awareness of the prevention of mother-to-child transmission of HIV infection programme 
(Chopra 2008:19).  
 
With regard to service integration, 79 (60.7%) of patients who participated in this survey 
agreed that there is integration of HAART services prioritised in antenatal services, 21 
(16.1%) disagreed with the statement while 30 (23.0%) were uncertain. The results 
suggest that there is integration of HAART services prioritised in antenatal services. The 
integration of HAART services should be prioritised in ANC services; however, where 
this is not feasible specific models should work towards intensifying follow-up of 
patients. This could be achieved through regular ANC service providers’ provision that 
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ensure same day services for all women receiving CD4 counts that make them eligible 
for HAART; and active tracing of pregnant women who are eligible for HAART to ensure 
that they complete referrals for HIV treatment (Stinson et al 2008:3).  
 
The finding of this study indicate that 103 (79.2%) of patients agreed that there is 
community acceptance of HIV voluntary counselling and testing services, 14 (10.7%) 
disagreed with the statement and 13 (10.0%) were uncertain. The results mean that 
there is community acceptance of HIV voluntary counselling and testing.  Such findings 
can be compared to the study conducted by Nyblade and Field-Nguer (2007:37) that 
revealed that directors and staff of PMTCT programs should recognise the influence 
that general community attitudes toward people living with HIV/AIDS have on women’s 
participation. They should seek to improve community acceptance of HVCT and 
community support of people with HIV/AIDS.  
 
Over three quarter (88.4%) of patients agreed that rapid HIV test is the first choice for 
routine testing, 9 (6.9%) disagreed with the statement and 6 (4.62%) were uncertain. 
These results indicate that rapid HIV test is the first choice in routine testing. Rapid HIV 
tests should be accurate, simple to perform and provide results immediately. For this 
reason, the rapid HIV test is now the first choice for routine testing. For a pregnant 
woman arriving late in pregnancy, early in labour or immediately postpartum, the rapid 
test is the only option to get an HIV test result in time to intervene effectively for PMTCT 
(MoHSS 2008:7).  
 
The results of the current survey as reflected in table 4.5 indicate that the majority 
(77.69%) of the patients agreed that the health centre provide MD-ARV for PMTCT of 
HIV infection, 12 (9.2%) of the patients disagreed with this statement and 17 (13.0%) 
were uncertain. The findings indicate that there is effective use MD-ARV for PMTCT of 
HIV infection. In November 2009, WHO issued revised guidelines emphasising the use 
of MD-ARV for PMTCT as well as the critical need for measuring antenatal CD4 cell 
counts to determine HAART eligibility. The WHO report in 2009 also demonstrated that 
regardless of the model of PMTCT service delivery, it is feasible to transition from SD-
NVP regimen to more effective MD-ARV regimen in a resource limited, public sector 




As shown in table 4.5, the study results show that 115 (88.4%) of the patients who 
participated in this survey agreed that HIV-infected pregnant women are counselled 
regarding the benefits of antiretroviral therapy for prevention of perinatal transmission, 5 
(3.8%) of the patients disagreed with the statement and 10 (7.6%) were uncertain. The 
results suggest that HIV-infected pregnant women are counselled regarding the benefits 
of antiretroviral therapy. HIV-infected pregnant women should be counselled regarding 
the benefits of ART for prevention of perinatal transmission even when initiation of ART 
is not recommended or considered optional on the basis of current guidelines for 
treatment of non pregnant persons (Public Health Service Task Force 2009:19). 
 
As shown in table 4.5, an overwhelming majority (81.5%) of patients stated that 
antiretroviral drugs are always available for interventions in reduction of HIV infection 
transmission, 9 (6.9%) disagreed with the statement while 15 (11.5%) were uncertain. 
The results are indication that antiretroviral drugs are always available. MTCT can occur 
during pregnancy and in the developed countries PMTCT has decreased to 
approximately 1 or 2% after implementation of universal prenatal ARV prophylaxis 
(Aikhionbare, Kumaresan, Shamsa & Bond 2006:3).  However, factors primarily related 
to logistics, costs and access have limited the impact of these interventions in 
developing countries. Although it remains important to continue to pursue strategies to 
make effective ARV interventions available in developing countries, an efficacious 
vaccine would surely be highly valuable for reduction of transmission and certainly 
would be the best strategy for reducing infection spread worldwide among adults 





4.3.3 Interventions to effective prevention of intrapartum HIV transmission 
 
Table 4.6 HCWs’ responses on interventions to effective prevention of 





Frequency Percent  
Intrapartum intravenous ZDV is recommended for all HIV-
infected pregnant women. 
  
Agreed  12 40.00 
Disagreed 15 50.00 
Uncertain 3 10.00 
Total 30 100.00 
Administration of single-dose nevirapine, zidovudine or 
lamivudine for women in labour is strategy for the PMTCT. 
  
Agreed 22 73.33 
Disagreed 8 26.67 
Total 30 100.00 
Women without documented HIV status at the time of labour are 
screened with rapid HIV testing. 
  
Agreed 26 86.67 
Disagreed 4 13.33 
Total 30 100.00 
There is cesarean intervention for the PMTCT of HIV among HIV-
infected women not taking antiretrovirals. 
  
Agreed 8 26.67 
Disagreed 13 43.33 
Uncertain 9 30.00 
Total 30 100.00 
Lowering the viral load by antenatal antiretroviral therapy is a 
critical component of PMTCT of HIV infection. 
  
Agreed 25 83.33 
Disagreed 2 6.67 
Uncertain 3 10.00 
Total 30 100.00 
HIV-infected women who had not received antepartum 
antiretroviral therapy start receiving intravenous ZDV 
immediately to prevent perinatal HIV transmission. 
  
Agreed 5 16.67 
Disagreed 17 56.67 
Uncertain 8 26.67 
Total 22 100.00 
 
The results in table 4.6 indicate that 12 (40.0%) of the HCWs agreed that intrapartum 
intravenous ZDV is recommended for all HIV-infected pregnant women, 15 (50.0%) 
disagreed with the statement and 3 (10.0%) were uncertain. The results indicate that 
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intrapartum intravenous ZDV is rarely recommended for all HIV-infected pregnant 
women. Intrapartum intravenous AZT is recommended for all HIV-infected pregnant 
women, regardless of their antepartum regimen to reduce perinatal HIV transmission. 
For women who are receiving a d4T-containing antepartum regimen, d4T should be 
discontinued during labour while intravenous AZT is being administered (Public Health 
Service Task Force 2009:59). Women who are receiving an antepartum combination 
ART regimen should continue this regimen on schedule as much as possible during 
labour and prior to scheduled caesarean section (Public Health Service Task Force 
2009:59).  
 
As shown in table 4.6, 22 (73.3%) of HCWs agreed that administration of single-dose 
nevirapine, zidovudine or lamivudine for women in labour is strategy for the PMTCT, 8 
(26.6%) disagreed with the statement. The results implied that administration of single-
dose nevirapine, zidovudine or lamivudine for women in labour is strategy for the 
PMTCT. Although combined antenatal, perinatal and neonatal interventions offer 
optimal protection from MTCT, intrapartum regimens such as SD-NVP or AZT/3TC for 
women in labour and their newborns remain the main strategy for the PMTCT (Homsy 
et al 2006:149).  
 
As shown in table 4.6, the finding of this study indicated that 26 (86.6%) of HCWs 
agreed that women without documented HIV status at the time of labour are screened 
with rapid HIV testing, 4 (13.3%) disagreed with the statement. The results indicate that 
women without documented HIV status at the time of labour are screened with rapid 
HIV testing. Any woman without documented HIV status at the time of labour should be 
screened with rapid HIV testing unless she declines or opt-out screening (Public Health 
Service Task Force 2009:60).  
 
As shown in table 4.6, 8 (26.6%) of HCWs agreed by stating that there are  caesarean 
section interventions for the PMTCT of HIV among HIV-infected women not taking 
antiretroviral drugs, 13 (43.3%) disagreed with this statement and 9 (30.0%) were 
uncertain. The results mean that there are rarely caesarean section interventions for the 
PMTCT. The caesarean section before labour and before ruptured membranes has 
been introduced as an intervention for the PMTCT. The role of mode of delivery in the 
management of HIV infected women should be assessed in light of risks as well as 
benefits, since HIV infected pregnant women must be provided with available 
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information with which to make informed decisions regarding caesarean section and 
other options to prevent transmission of infection to their children (Read & Newell 
2007:2).  
 
The majority (83.3%) of the HCWs agreed that lowering the viral load by antenatal 
antiretroviral therapy is a critical component of PMTCT of HIV infection, 2 (6.6%) 
disagreed with the statement and 3 (10.0%) were uncertain. The results suggest 
indicate that lowering the viral load by antenatal antiretroviral therapy is a critical 
component of PMTCT. In women with high viral loads, it is likely that lowering the viral 
load by antenatal ART is a critical component of protection (The Independent Expert 
Panel 2010:10). However, ARV drugs have been shown to reduce the risk of 
transmission. Additionally, the level of HIV RNA at delivery and use of antenatal ART 
are each independently associated with the risk of transmission, suggesting that ARV 
prophylaxis does not work solely through reduction in viral load (The Independent 
Expert Panel 2010:10).  
 
As shown in table 4.6, the results of this study show that 5 (16.6%) of HCWs agreed 
that HIV-infected women who had not received antepartum antiretroviral therapy start 
receiving intravenous ZDV immediately to prevent perinatal HIV transmission, 17 
(56.6%) of the  HCWs disagreed with the statement and 8 (26.6%) were uncertain. The 
results mean that rarely HIV-infected women who had not received antepartum 
antiretroviral therapy start receiving intravenous ZDV immediately to prevent perinatal 
HIV transmission. All HIV-infected women who have not received antepartum ARV 
should have intravenous AZT started immediately to prevent perinatal HIV transmission. 
Although intrapartum or neonatal antiretroviral medications will not prevent perinatal 
transmission that occurs before labour, most transmission occurs near to or during 
labour and delivery. Pre-exposure prophylaxis for the fetus can be provided by giving 
the mother a drug that rapidly crosses the placenta to produce systemic ARV drug 
levels in the fetus during intensive exposure to HIV in maternal genital secretions and 





Table 4.7 Patients’ responses on interventions to effective prevention of 
intrapartum HIV transmission (n=130)  
 
CHARACTERISTICS Frequency Percentage 
There are obstetrical interventions for PMTC of HIV infection.   
Agreed  111 85.38 
Disagreed 3 10.00 
Uncertain 6 4.62 
Total 130 100.00 
There is administration of short course of AZT to pregnant mothers 
before birth in order to reduce HIV transmission. 
  
Agreed 111 85.38 
Disagreed 6 4.62 
Uncertain 13 10.00 
Total 130 100.00 
There is understanding and knowledge of the mechanism in the 
timing of preventing mother-to-child transmission of HIV infection. 
  
Agreed 115 88.46 
Disagreed 6 4.62 
Uncertain 9 6.92 
Total 130 100.00 
There is administration of short course monotherapy regimes from 
36 weeks gestation to reduce HIV transmission. 
  
Agreed 87 66.92 
Disagreed 14 10.77 
Uncertain 29 22.31 
Total 130 100.00 
HIV transmission is prevented by treating the pregnant woman 
during the third trimester, delivery and by giving the child 
prophylactic. 
  
Agreed 101 77.69 
Disagreed 10 7.69 
Uncertain 19 14.62 
Total 130 100.00 
HIV transmissions at different stages are prevented by the use of 
prophylactic interventions with combination of antiretroviral 
therapy. 
  
Agreed 105 80.77 
Disagreed 7 5.38 
Uncertain 18 13.85 
Total 130 100.00 
 
Patients were asked if there are obstetrical interventions for PMTC of HIV infection. As 
shown in table 4.7, 111 (85.3%) of patients agreed, 3 (10.0%) disagreed with the 
statement and 6 (4.6%) were uncertain. The results mean that there is an effective 
obstetrical intervention for PMTC. Improving obstetrical practice entails working closely 
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with safe motherhood programs to develop and disseminate appropriate guidelines 
which address HIV and PMTCT, skills building and ensuring that health workers have 
the supplies they need to safeguard their clients and themselves (Rutenberg et al 
2006:49).  
 
Table 4.7 shows that 111 (85.3%) of patients agreed that there is administration of short 
course of AZT to pregnant mothers before birth in order to reduce HIV transmission, 6 
(4.6%) disagreed with the statement and 13 (10.0%) were uncertain. The results 
indicate that there is effective administration of short course of AZT to pregnant 
mothers. Short course of AZT to pregnant mothers shortly before birth and to the babies 
after birth reduces HIV transmission. In the light of this, the decision of government to 
deny prospective mother access to AZT on the grounds that it is too expensive and 
difficult to implement is controversial (Adler & Qulo 2007:308).  
 
As shown in table 4.7, 115 (88.4%) of patients agreed that there is understanding and 
knowledge of the mechanism in the timing of PMTCT of HIV infection, 6 (4.6%) 
disagreed with the statement and 9 (6.9%) were uncertain. The results mean that there 
is effective understanding and knowledge of the mechanism in the timing of PMTCT. In 
the absence of antiviral prophylaxis, the risk of MTCT is about 25%. The use of 
antiretroviral prophylaxis in women during pregnancy and in their infants after birth has 
lowered the risk of transmission (Prasitwattanaseree et al 2006:179).  However, the 
mechanism of protection provided by AZT is not completely understood. Therefore, 
knowledge of the timing of MTCT is critical to better understand the mechanism of 
protection and important to optimise prevention (Prasitwattanaseree et al 2006:179).  
 
As shown in table 4.7, 87 (66.9%) of patients agreed that there is administration of short 
course monotherapy regimes from 36 weeks gestation to reduce HIV transmission, 14 
(10.7%) disagreed with the statement and 29 (22.3%) were uncertain. The results mean 
that there is administration of short course monotherapy regimes. Short course 
monotherapy regimes with either AZT from 36 weeks gestation, through labour and 
delivery or NVP given as a single dose to the mother during labour and once to the 
baby reduce transmission at six weeks (Chopra 2008:11).  
 
The  results of this study as refers to table 4.7, show that most of the patients (77.69%) 
agreed that HIV transmission is prevented by treating the pregnant woman during the 
 
59 
third trimester, delivery and by giving the child prophylactic, 10 (7.69%) disagreed with 
the statement and 19 (14.6%) were uncertain. The results indicate that HIV 
transmission is prevented by treating the pregnant woman during the third trimester, 
delivery and by giving the child prophylactic.  MTCT mainly occurs during the third 
trimester of pregnancy or at delivery in the absence of breastfeeding. Transmission can 
be prevented by treating the pregnant woman during the third trimester, at delivery and 
by giving the child prophylactic treatment during the first weeks of life. Short-course 
NVP exposure may be beneficial with respect to driving immune activation before the 
establishment of an infection in an infant exposed to HIV, but may have some 
detrimental consequences in the case of existing infection acquired in utero (Schramm, 
Kuhn, Gray & Tiemessen 2008:3).  
 
An overwhelming majority of the surveyed patients (80.77%) as table 4.7 indicates that 
agreed that HIV transmissions at different stages are prevented by the use of 
prophylactic interventions with combination of antiretroviral therapy, 7 (5.3%) disagreed 
with the statement and 18 (13.8%) were uncertain. The results mean that HIV 
transmissions at different stages are prevented by the use of prophylactic interventions 
In the absence of treatment or prophylaxis, most transmissions are thought to occur 
during the intrapartum period. The proportions of transmission at different stages are 
changed by the use of prophylactic interventions with combination of ART almost 
eliminating antepartum and intrapartum transmission and shortcourse ARVs having less 
effect on antepartum transmission, although achieving a major reduction in intrapartum 





4.3.4 Interventions to prevent postpartum HIV transmission 
 
Table 4.8 HCWs’ responses on interventions to effective prevention of 
postpartum HIV transmission (n=30) 
 
CHARACTERISTICS Frequency Percent  
Infants exposed to HIV receive antiretroviral drugs during 
breastfeeding. 
  
Agreed 25 83.33 
Disagreed 3 10.00 
Uncertain 2 6.67 
Total 30 100.00 
HIV-exposed infants are being identified who require HIV diagnosis 
and follow-up care. 
  
Agreed 25 83.33 
Disagreed 3 10.00 
Uncertain 2 6.67 
Total 30 100.00 
There is HIV antibody testing for diagnosis of HIV infection in 
children less than18 months old. 
  
Agreed 19 63.33 
Disagreed 8 26.67 
Uncertain 3 10.00 
Total 30 100.00 
HIV infected mothers are given highly active antiretroviral treatment 
during the breast-feeding period. 
  
Agreed 13 43.33 
Disagreed 13 43.33 
Uncertain 4 13.33 
Total 30 100.00 
Infants exposed to HIV receive cotrimoxazole prophylaxis starting at 
4-6 weeks of age. 
  
Agreed 16 53.33 
Disagreed 12 40.00 
Uncertain 2 6.67 
Total 30 100.00 
Newborn from an HIV-infected mother receives single-dose 
Nevirapine between 12-72 hours. 
  
Agreed 23 76.67 
Disagreed 4 13.33 
Uncertain 3 10.00 
Total 30 100.00 
HIV-exposed infants receive postpartum antiretroviral drugs to 
reduce perinatal HIV transmission. 
  
Agreed 20 66.67 
Disagreed 5 16.67 
Uncertain 5 16.67 




HCWs were asked if infants exposed to HIV receive antiretroviral drugs during 
breastfeeding. As shown in table 4.8, 25 (83.3%) of the HCWs agreed, 3 (10.0%) 
disagreed with the statement and 2 (6.6%) were uncertain. The results mean that 
infants exposed to HIV receive antiretroviral drugs. Two potential prevention strategies 
in resource-limited settings are provision of antiretroviral drugs to infants exposed to 
HIV during breastfeeding and provision of combination ART to lactating women. 
Exclusive breastfeeding has been shown to lower the risk of postnatal HIV transmission 
compared to mixed feeding, but does not eliminate risk (The Independent Expert Panel 
2010:17).  
 
Table 4.8 shows that 25 (83.3%) of the HCWs agreed that HIV-exposed infants are 
being identified who require HIV diagnosis and follow-up care, 3 (10.0%) disagreed with 
the statement and 2 (6.6%) were uncertain. The results indicate that HIV-exposed 
infants are being identified who require HIV diagnosis. As a result of the programme for 
the PMTCT, a large number of HIV-exposed infants are being identified who require HIV 
diagnosis and follow-up care. It is important to identify young infants with HIV infection 
early and to refer them for ART because of the high mortality from untreated HIV/AIDS. 
It is also important to promptly identify young infants who are not HIV-infected in order 
to reassure their parents, discharge them from costly follow-up and measure the overall 
effectiveness of the PMTCT programme (MoHSS 2008:29).  
 
As shown in table 4.8, 19(63.3%) of HCWs agreed that there is HIV antibody testing for 
diagnosis of HIV infection in children less than18 months old, 8 (26.6%) disagreed with 
the statement and 3 (10.0%) were uncertain. The results mean that there is HIV 
antibody testing for diagnosis of HIV infection in children. HIV antibody testing gives 
definitive results for diagnosis of HIV infection in children less than 18 months old. As 
such this is the recommended testing approach for the diagnosis or exclusion of HIV in 
this age group. It is important to remember that HIV-exposed children less than18 
months old who have had prolonged breastfeeding would need to have a negative HIV 
antibody test result at least 3 months after breastfeeding is discontinued to exclude HIV 
infection (MoHSS 2010:45).  
 
As shown in table 4.8, the study results show that 13 (43.3%) of HCWs agreed that HIV 
infected mothers are given HAART treatment during the breast-feeding period, 13 
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(43.3%) disagreed with the statement and 4 (13.3%) were uncertain. The results 
indicate that HIV infected mothers are rarely given HAART treatment. Another approach 
to prevent HIV transmission during breast-feeding that is now under evaluation is to give 
HAART to HIV-infected mothers during the breast-feeding period even if they do not 
need HAART for their own health (Kilewo, Karlsson, Massawe, Lyamuya, Swai, Fred 
Mhalu & Biberfeld 2008:1).  
 
The result of this study as shown in table 4.8, slightly above half (53.33%) of the HCWs 
agreed that infants exposed to HIV receive cotrimoxazole prophylaxis starting at 4-6 
weeks of age, 12 (40.0%) disagreed with the statement and 2 (6.67%) were uncertain. 
The results further show that infants exposed to HIV receive cotrimoxazole prophylaxis. 
All infants exposed to HIV should receive cotrimoxazole prophylaxis starting at 4-6 
weeks of age and continuing until HIV infection is excluded. Cotrimoxazole can reduce 
child mortality in HIV positive children by over 40%. However, although cotrimoxazole is 
widely available and is affordable, the progress of its provision for prophylaxis in infants 
exposed to HIV and HIV positive mothers is still slow (UNICEF 2007:4). 
 
 The majority of the surveyed HCWs (76.6%) agreed that newborn from an HIV-infected 
mother receives single-dose Nevirapine between 12-72 hours, 4 (13.3%) disagreed with 
the statement and 3 (10.0%) were uncertain. The results mean that newborn from an 
HIV-infected mother receives single-dose Nevirapine. The newborn from an HIV-
infected mother should receive SD-NVP mg/kg between 12-72 hours after delivery if 
mother has received Nevirapine at least 2 hours before delivery. In addition, the baby 
should receive a tail of AZT/3TC BD for 7 days (MoHSS 2008:23).  If an HIV-infected 
mother has not received Nevirapine more than two hours before delivery and the 
newborn presents at the health facility less than 24 hours of age, the newborn should 
receive a stat dose of Nevirapine syrup and a second dose at 48-72 hours. In addition 
the infant should be given AZT/3TC for 7 days and AZT 4 mg/kg + 3TC 2 mg/kg every 
12 hours (MoHSS 2008:23).  
 
As shown in table 4.8, the study results reveal that 20 (66.6%) of HCWs agreed that 
HIV-exposed infants receive postpartum antiretroviral drugs to reduce perinatal HIV 
transmission, while equal proportions of 5 (16.67%) disagreed with the statement and 
were uncertain. All HIV-exposed infants should receive postpartum antiretroviral drugs 
to reduce perinatal HIV transmission. The 6-week neonatal AZT chemoprophylaxis 
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regimen is recommended for all HIV-exposed infants. Infants born to mothers who have 
received standard antepartum and intrapartum ARV prophylaxis and have undetectable 
viral load are at very low risk of HIV transmission (Public Health Service Task Force 
2009:76).  
 
Table 4.9 Patient’s responses on interventions to effective prevention of 
postpartum HIV transmission (n=130)  
 
CHARACTERISTICS Frequency Percent  
Women are educated about exclusive breastfeeding prior to delivery.   
Agreed 93 71.54 
Disagreed 8 6.15 
Uncertain 29 22.31 
Total 130 100.00 
Prevention of mother-to-child transmission of HIV infection 
represents an entry point for improving overall family health. 
  
Agreed 107 82.31 
Disagreed 6 4.62 
Uncertain 17 13.08 
Total 130 100.00 
 
As shown in table 4.9, the majority of the surveyed patients (71.5%) agreed that women 
are educated about exclusive breastfeeding prior to delivery, 8 (6.1%) disagreed with 
the statement and 29 (22.3%) were uncertain. The results imply that women are 
educated about exclusive breastfeeding. Infant formula is already modified to meet the 
infant’s nutritional needs while cow’s and goat’s milk need to be modified for the first 6 
months. The baby on exclusive replacement feeding also needs additional water and 
daily multivitamin and mineral supplements. An HIV positive mother may choose to 
breastfeed her baby if she considers it to be the best way of feeding. If the mother 
chooses to breastfeed, she should be educated about exclusive breastfeeding prior to 
delivery and be provided with support and encouragement (MoHSS 2008:24).  
 
As shown in table 4.9, the study results show that 107 (82.3%) of patients agreed that 
PMTCT of HIV infection represents an entry point for improving overall family health, 6 
(4.6%) disagreed with the statement and 17 (13.0%) were uncertain. The results mean 
that PMTCT of HIV infection represents an entry point for improving overall family 
health. PMTCT represents an entry point for improving overall family health and 
functioning. Family-focused approaches facilitate broader implementation of PMTCT 
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programming, addressing the comprehensive needs of women, particularly those in 
need of treatment for their own health, as well as of children and other family members, 
over time. A paradigm shift is needed in PMTCT which considers the needs of entire 
families, rather than placing a singular focus on PMTCT during pregnancy and delivery 
(Betancourt et al 2010:1).  
  
4.4  CONCLUSION 
 
This chapter focussed on the analysis of the results obtained from the empirical study 
through the research questionnaires. The result of each question from questionnaires 
was analysed, presented in the form of tables. The chapter also provided the 
discussions and interpretations of the research findings. The studies found that there 
were mixed perceptions of respondents for effective antepartum HIV transmission, 
intrapartum HIV transmission and postpartum HIV transmission prevention interventions 
programmes to PMTCT. The following chapter will focus on summary, conclusions, 







SUMMARY, CONCLUSIONS, RECOMMENDATIONS AND LIMITATIONS 
OF THE STUDY 
  
 
5.1 INTRODUCTION  
 
This chapter lays out the summary of the research findings, conclusions drawn from the 
research findings and contributions of the study. The study limitations and the 
recommendations with PMTC interventions implications have been described as well as 
recommendations for further research are provided in this chapter. 
 
5.2 SUMMARY  
 
In chapter 1 the nature of the problem, which formed the basis of the study, was 
presented. The purpose of this study was to provide an idea and understanding of the 
importance of effective interventions to prevent antepartum, intrapartum and postpartum 
HIV transmission. It was also to focus on providing explanation regarding the advantage 
of the PMTCT concepts. This research has dealt with the objectives of the study which 
were to investigate the challenges faced in the interventions for PMTCT of HIV infection, 
to describe the strategies used in the PMTCT of HIV infection and to recommend 
effective measures to promote the interventions on the PMTCT of HIV infection. Based 
on the aim, objectives and research questions of the study, this research was worth to 
be conducted at Oshakati District Health Centre.  
 
The study was able to indicate the condition of PMTCT interventions at Oshakati District 
Health Centre mainly in relation to interventions to prevent antepartum, intrapartum and 
postpartum HIV transmission. Overall, the finding of the study showed that there is 
effective PMTCT at Oshakati District Health Centre. It also became known that Oshakati 
District Health Centre’ PMTCT interventions rarely use ELISA that is widely used in 
PMTCT, intrapartum intravenous ZDV is rarely recommended for all HIV-infected 
pregnant women,  rarely use of caesarean section intervention for the PMTCT. The 
results of the study brought forth the following major findings. 
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5.2.1 Participants demographics 
 
The research finding has shown that majority of the participants from the HCWs and 
patients group were females. Only one female patient was accompanied by a male 
partner. Most of the participants were black.  Both HCWs and patients who participated 
in this survey were mostly young between the ages of 20-40. More than three quarter of 
the HCWs were certificate holders and above. A great number of health workers had 1-
5 years of experience.  
 
5.2.2 Responses on interventions to effective prevention of  antepartum HIV 
transmission 
 
The results showed that the majority of HCWs agreed that most women come for 
antepartum care and access HIV counselling and testing services. The findings reveal 
that over three quarter of HCWs agreed that the importance of adherence to the 
antiretroviral treatment during pregnancy is emphasised and HIV testing and 
counselling is provided to all pregnant women as a routine comprehensive package of 
care and management of HIV in women evolve the use of HAART. A higher percentage 
of HCWs agreed that the antenatal services undertake clinical assessment for HIV signs 
and symptoms and obtain a baseline CD4 _ cell count. Majority of the patients agreed 
that there is presence of high quality voluntary counselling and testing service. The 
study showed that majority of the patients agreed that there is community acceptance of 
HIV voluntary counselling and testing and more than three quarter of patients agreed 
that rapid HIV test is the first choice for routine testing. Majority of patients agreed that 
HIV-infected pregnant women are counselled regarding the benefits of antiretroviral 
therapy for prevention of perinatal transmission. There were a higher percentage of 
patients stating that antiretroviral drugs are always available for interventions in 
reduction of HIV infection transmission. 
 
However, a minority of HCWs expressed concern that there is an inadequate male 
partners’ involvement in PMTCT programme. The study also showed that about one-
fifth of the HCWs agreed that couple HIV counselling and testing that increase 
acceptance of testing by pregnant women is rarely done. In addition, about one-fifth of 
patients disagreed that there is integration of HAART services prioritised in antenatal 




5.2.3 Responses on interventions to effective prevention of intrapartum HIV 
transmission 
 
From the findings of this study, HCWs agreed that women without documented HIV 
status at the time of labour are screened with rapid HIV testing. The majority of staff 
agreed that lowering the viral load by antenatal antiretroviral therapy is a critical 
component of PMTCT of HIV infection. The large proportion of patients agreed that 
there are obstetrical interventions for PMTC of HIV infection. There was a higher 
percentage of patients that agreed that there is administration of short course of AZT to 
pregnant mothers before birth in order to reduce HIV transmission. The majority of the 
patients stated that there is understanding and knowledge of the mechanism in the 
timing of PMTCT of HIV infection.  
 
However, minority of HCWs expressed concern that administration of single-dose 
nevirapine, zidovudine or lamivudine for women in labour is rarely a strategy for the 
PMTCT. The study result indicated that staff agreed that intrapartum intravenous ZDV is 
rarely recommended for all HIV-infected pregnant women or when in labour. Only small 
proportion of the HCWs agreed that caesarean section is used as an intervention for the 
MTCT of HIV among HIV-infected women not taking antiretroviral drugs.  
 
5.2.4 Responses on interventions to effective prevention of postpartum HIV 
transmission  
 
There were a higher percentage of patients agreeing that women are educated about 
exclusive breastfeeding prior to delivery. Majority of patients agreed that PMTCT of HIV 
infection represents an entry point for improving overall family health. Only small 
proportion of the HCWs agreed that HIV-exposed infants are being identified who 
require HIV diagnosis and follow-up care.  
 
The study also showed that about one-third of the HCWs disagreed that HIV antibody 
testing for diagnosis of HIV infection in children less than18 months old is widely used. 
Half of the HCWs surveyed disagreed HIV infected mothers are given HAART treatment 
during the breast-feeding period. The minority of the HCWs disagreed that infants 
exposed to HIV receive cotrimoxazole prophylaxis as early as 4-6 weeks of age. Only 
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small proportion of the HCWs disagreed that HIV-exposed infants receive postpartum 
antiretroviral drugs to reduce perinatal HIV transmission. 
 
5.3 CONCLUSIONS  
 
The evidence above demonstrated that antepartum, intrapartum and postpartum HIV 
transmission interventions for effective PMTCT is still a challenge. From the findings of 
this study, it emerged that the majority of staff and patients perceive that there is 
effective PMTCT. However, Oshakati District Health Centre has challenges of male 
partners’ involvement in PMTCT programme, couple HIV counselling and testing that 
increase acceptance of testing by pregnant women; integration of HAART in antenatal 
services for effective interventions to prevent antepartum HIV transmission.  
 
Oshakati District Health Centre has challenges administering intrapartum intravenous 
ZDV and performing caesarean section recommended for HIV-infected pregnant 
women effective interventions to prevent intrapartum HIV transmission. Oshakati District 
Health Centre has challenges giving antiretroviral drugs during breastfeeding to HIV 
exposed infants and rarely identified those who require HIV diagnosis and follow-up 
care, provision of cotrimoxazole prophylaxis starting at 4-6 weeks of age, and HIV-
exposed infants rarely receive postpartum antiretroviral drugs to reduce perinatal HIV 
transmission for effective prevention of postpartum HIV transmission. 
 
5.4 RECOMMENDATIONS  
 
The following recommendations were made in order to achieve effective PMTCT at 
Oshakati District Health Centre based on the findings of this study:  
 
I INTERVENTIONS TO EFFECTIVE PREVENTION OF ANTEPARTUM HIV 
TRANSMISSION 
 
• Promoting strategies that will increase involvement of male partners in PMTCT of 
HIV infection programmes that may improve uptake, behaviour change and 
compliance with HIV preventive measures. 
• Strengthening couple counselling and testing that has been shown to increase 
acceptance of HIV testing by pregnant women. 
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• The integration of HAART services should be prioritised in ANC services and 
specific models should work towards intensifying follow-up of patients. This could 
be achieved through regular ANC service providers ensuring same day services 
for all women receiving CD4 counts that make them eligible for HAART and 
active tracing of pregnant women who are eligible for HAART to ensure that they 
get to facilities where they are referred for HIV treatment. 
• Strengthening administration of antepartum short course monotherapy regimes 
with AZT prophylaxis earlier to women not eligible for HAART. 
 
II INTERVENTIONS TO EFFCETIVE PREVENTION OF INTRAPARTUM HIV 
TRANSMISSION 
 
• Promoting proper administration of single-dose nevirapine, zidovudine or 
lamivudine for women in labour as a strategy for the PMTCT because 
intrapartum regimens such as SD-NVP or AZT/3TC for women in labour lower 
maternal HIV viral load  thereby reduce risk of transmitting HIV to her baby during 
labour and delivery. 
• Intrapartum intravenous AZT should be recommended for all HIV-infected 
pregnant women, regardless of their antepartum regimen to reduce perinatal HIV 
transmission. Women who are receiving an antepartum combination ART 
regimen should continue this regimen on schedule as much as possible during 
labour and prior to scheduled caesarean section. 
• The caesarean section before labour and before ruptured membranes should be 
introduced as an intervention for the PMTCT. The role of mode of delivery in the 
management of HIV infected women should be assessed in light of risks as well 
as benefits since HIV infected pregnant women must be provided with available 
information with which to make informed decisions regarding caesarean section 
and other options to prevent transmission of infection to their children. 
• All HIV-infected women who have not received antepartum ARV should have 
intravenous AZT started immediately to prevent perinatal HIV transmission 
although intrapartum or neonatal antiretroviral medications will not prevent 
perinatal transmission that occurs before labour since most transmission occurs 




III INTERVENTIONS TO EFFECTIVE PREVENTION OF POSTPARTUM HIV 
TRANSMISSION 
 
• Promoting the provision of antiretroviral drugs to infants exposed to HIV during 
breastfeeding and provision of combination ART to lactating women because 
these are two potential prevention strategies recommended in the PMTCT in the 
resource-limited settings. 
• Increasing emphasis on identifying HIV-exposed infants who require HIV 
diagnosis and follow-up care and to refer HIV-exposed infants for ART because 
of the high mortality from untreated HIV/AIDS and identifying young infants who 
are not HIV-infected in order to reassure their parents, discharge them from 
costly follow-up measures. 
• Strengthening HIV antibody testing that gives definitive results for diagnosis of 
HIV infection in children less than 18 months old because this is the 
recommended testing approach for the diagnosis or exclusion of HIV in this age 
group. 
• Increasing emphasis of giving HAART to HIV-infected mothers during the breast-
feeding period even if they do not need HAART for their own health. 
• All infants exposed to HIV should receive cotrimoxazole prophylaxis starting at 4-
6 weeks of age and continuing until HIV infection is excluded because 
cotrimoxazole reduce child mortality in HIV positive children by over 40%. 
• The newborn from an HIV-infected mother should receive SD-NVP mg/kg 
between 12-72 hours after delivery if mother has received Nevirapine at least 2 
hours before delivery.  
• All HIV-exposed infants should be receiving postpartum antiretroviral drugs to 
reduce perinatal HIV transmission.  
 
IV FURTHER RESEARCH  
 
It is envisaged that this study can lay the foundation for further research within the 
interventions to prevent antepartum, intrapartum and postpartum HIV transmission to 
prevent MTCT. The interventions to prevent antepartum, intrapartum and postpartum 
HIV transmission in hospitals/Health Centres/Clinics could roll-out or introduce the 
questionnaire in all healthcare centres and the results obtained from staff and patients’ 
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perception on the effectiveness of the PMTCT programme could be segmented 
nationally, per region or per district. 
 
Alternatively, hospitals/health centres/clinics could also determine the extent to which 
their interventions to prevent antepartum, intrapartum and postpartum HIV transmission 
effectively contribute to PMTCT. The benefits of the results can assist the 
hospitals/Health centre and Clinics to effectively PMTCT of HIV infection. 
 
5.5 CONTRIBUTIONS OF THE STUDY  
 
This study has made the following contributions: 
 
• Important contributions to Oshakati District Health Centre and other 
hospitals/Health Centres/Clinics in terms of benchmarking their interventions to 
prevent antepartum, intrapartum and postpartum HIV transmission to effectively 
prevent MTCT. 
• Contribution towards the reduction of the spread of HIV infections through 
improvement of interventions for PMTCT programmes in Namibia. 
• Based on findings, Oshakati District Health Centre now recognises its strong and 
weak points for effective PMTCT of HIV infection. 
• Academically, the study findings have helped the researcher in designing 
relevant recommendations to Oshakati District Health Centre for effective 
PMTCT of HIV infection. 
• From the Namibian government point of view, this study will serve as a useful 
(baseline) reference material to provide appropriate strategic interventions to 
prevent antepartum, intrapartum and postpartum HIV transmissions for effective 
PMTCT of HIV infection. 
 
5.6 IMPLICATION OF THE STUDY 
 
• The result of this study shows the need to increase male involvement in PMTCT, 
increase couple counselling and integration of HAART in ANC to overcome 
challenges to effective PMTCT during the antepartum period. 
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• Findings of this study also indicated that the need to perform elective Caesarean 
section as a delivery method for HIV infected women  and administration of 
intravenous AZT during labour to effective reduce MTCT. 
• Finally, the impact of this study have shown the need to overcome challenges to 
effective PMCT in the postpartum period by addressing infant feeding practices 
and strengthening provision of infant ARV prophylaxis. 
 
5.7 LIMITATIONS OF THE STUDY  
 
This study had the following limitations: 
 
• An assessment of effective PMTCT of HIV infection study was conducted at 
Oshakati District Health Centre only and other hospitals/Health Centres/Clinics 
were not included in the study. Research results therefore are limited to this 
particular District Health Centre and cannot be generalised to other 
hospitals/Health Centres/Clinics.  
• Another limitation was that nurses not experienced in PMCTC were not surveyed 
who might have knowledge in the PMTCT and this also affected the ability to 
generalise the results. 
• The study is limited to the interventions to prevent antepartum, intrapartum and 
postpartum HIV transmissions in order to contribute to PMTCT and did not 
include the general interventions to prevent HIV and AIDS such as enabling 
environment, impact mitigation services and integrated and co-ordinated 
programme management.  
 
5.8 CONCLUDING REMARKS  
 
The WHO (2008a:8) findings stress that HIV infection transmitted from an HIV-infected 
mother to her child during antepartum, intrapartum and postpartum period is known as 
MTCT. PMTCT of HIV infection is a highly effective intervention and has huge potential 
to improve both maternal and child health. The MOHSS (2008:6) emphasises that 
routine HIV testing and counselling is the cornerstone of all interventions to reduce 
MTCT of HIV infection. This is accompanied with appropriate involvement of male 
partners in PMTCT of HIV infection programmes, couple counselling and testing, 
integration of HAART services, administration of single-dose nevirapine, zidovudine or 
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lamivudine for women in labour, administration of short course monotherapy regimes, 
intrapartum intravenous AZT recommendations for all HIV-infected pregnant women, 
provision of antiretroviral drugs to infants exposed to HIV, identifying HIV-exposed 
infants who require HIV diagnosis and HIV antibody testing.  
 
The inadequate interventions to prevent antepartum, intrapartum and postpartum HIV 
transmissions to prevent MTCT could serve to inform the healthcare management to 
strengthen interventions to achieve the effective PMTCT through further focusing on 
improvements in the interventions which will be able to address the shortcomings in an 
innovative way. Therefore, due attention has to be given to all concerned stakeholders 
to promote involvement of male partners in PMTCT of HIV infection programmes, 
strengthening couple counselling and testing, integration of HAART services, promoting 
proper administration of single-dose nevirapine, zidovudine or lamivudine for women in 
labour, strengthening administration of short course monotherapy regimes, promoting 
the provision of antiretroviral drugs to infants exposed to HIV and increasing emphasis 
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ANNEXURE A: RESEARCH QUESTIONNAIRE FOR HEALTH CARE WORKERS 
EFFECTIVE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV 





Respondent Number:  
 









Not willing to disclose  
 
3 Please indicate to which of the following age groups you belong. 
Between 20-30 years  
Between 31-40 years  
Between 41-50 Years  
51 ears and older  
 
4 How long have you been working at Oshakati District Health Centre? 
Less than 1 year  
1-5 years  
6-10 years  
11-15 years  
2 
 
Over 15 years  
 
5 What is your highest qualification? 




Undergraduate degree  






INSTRUCTIONS FOR COMPLETING QUESTIONS OF SECTION B 
1 = Strongly Disagree 
2 = Disagree 
3 = Uncertain 
4 = Agree 
5 = Strongly Agree 
 
It is important to note that there are no right or wrong answers to this survey. Kindly 
rate the statements below which best indicate your views. 
 
QUESTION 1 – THE EXTENT TO WHICH ANTEPARTUM HIV TRANSMISSION 
PREVENTION INTERVENTIONS CONTRIBUTE TOWARDS PREVENTION OF 
MOTHER-TO-CHILD TRANSMISSION OF HIV INFECTION 
It is believed that antepartum HIV transmission prevention interventions programmes 
have made a major contribution to prevent mother-to-child transmission of HIV 
infection. I would like to find out your perception towards Oshakati District Health 
Centre antepartum HIV transmission prevention interventions. 
No. Item Strongly 
Disagree 




1 Most women come for 
antepartum care and 
access HIV counseling and 
testing services. 
     
2 The importance of 
adherence to the 
antiretroviral treatment 
during pregnancy is 
emphasized. 
     
3 There is male partners’ 
involvement in prevention 
of mother-to child 
transmission of HIV 
infection programme. 
     
4 There is couple HIV 
counseling and testing that 
increase acceptance of 
testing by pregnant women. 
     
5 HIV testing and counselling 
is provided to all pregnant 
women as a routine 
comprehensive package of 
care. 
     
6 Enzyme-Linked 
Immunosorbent Assay is 
used in prevention of 
mother-to child 
transmission of HIV 
infection. 
     
7 Management of HIV in 
women evolve the use of 
highly active antiretroviral 
therapy. 
     
8 The antenatal services 
undertake clinical 
assessment for HIV signs 
and symptoms and obtain a 
baseline CD4 _ cell count. 





QUESTION 2 – THE EXTENT TO WHICH INTRAPARTUM HIV TRANSMISSION 
PREVENTION INTERVENTIONS CONTRIBUTE TOWARDS PREVENTION OF 
MOTHER-TO-CHILD TRANSMISSION OF HIV INFECTION 
It is believed that intrapartum HIV transmission prevention interventions programmes 
have made a major contribution to prevent mother-to-child transmission of HIV 
infection. I would like to find out your perception towards Oshakati District Health 
Centre intrapartum HIV transmission prevention interventions. 
No. Item Strongly 
Disagree 
Disagree Uncertain Agree Strongly 
Agree 
1 Intrapartum intravenous 
ZDV is recommended for 
all HIV-infected pregnant 
women. 
     
2 Administration of single-
dose nevirapine, 
zidovudine or lamivudine 
for women in labour is 
strategy for the prevention 
of mother-to-child 
transmission of HIV 
infection. 
     
3 Women without 
documented HIV status at 
the time of labour are 
screened with rapid HIV 
testing. 
     
4 There is cesarean 
intervention for the 
prevention of mother-to-
child transmission of HIV 
among HIV-infected women 
not taking antiretrovirals. 
     
5 Lowering the viral load by 
antenatal antiretroviral 
therapy is a critical 
component of preventing 
mother-to-child 
transmission of HIV 




6 HIV-infected women who 
had not received 
antepartum antiretroviral 
therapy start receiving 
intravenous ZDV 
immediately to prevent 
perinatal HIV transmission. 
     
 
QUESTION 3 – THE EXTENT TO WHICH POSTPARTUM HIV TRANSMISSION 
PREVENTION INTERVENTIONS CONTRIBUTE TOWARDS PREVENTION OF 
MOTHER-TO-CHILD TRANSMISSION OF HIV INFECTION 
It is believed that postpartum HIV transmission prevention interventions programmes 
have made a major contribution to prevent mother-to-child transmission of HIV 
infection. I would like to find out your perception towards Oshakati District Health 
Centre     postpartum HIV transmission prevention interventions. 
No. Item Strongly 
Disagree 
Disagree Uncertain Agree Strongly 
Agree 




     
2 HIV-exposed infants are 
being identified who 
require HIV diagnosis and 
follow-up care. 
     
3 There is HIV antibody 
testing for diagnosis of 
HIV infection in children 
less than18 months old. 
     
4 HIV infected mothers are 
given highly active 
antiretroviral treatment 
during the breast-feeding 
period. 
     
5 Infants exposed to HIV 
receive cotrimoxazole 
prophylaxis starting at 4-6 
     
6 
 
weeks of age. 
6 Newborn from an HIV-
infected mother receives 
single-dose Nevirapine 
between 12-72 hours. 
     
7 HIV-exposed infants 
receive postpartum 
antiretroviral drugs to 
reduce perinatal HIV 
transmission. 
     
 







ANNEXURE B: RESEARCH QUESTIONNAIRE FOR PATIENTS 
EFFECTIVE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV 





Respondent Number:  









Not willing to disclose  
 
3 Please indicate to which of the following age groups you belong. 
Under 20 years  
Between 20-30 years  
Between 31-40 years  
Between 41-50 Years  




INSTRUCTIONS FOR COMPLETING QUESTIONS OF SECTION B 
1 = Strongly Disagree 
2 = Disagree 
3 = Uncertain 
2 
 
4 = Agree 
5 = Strongly Agree 
 
It is important to note that there are no right or wrong answers to this survey. Kindly 
rate the statements below which best indicate your views. 
 
QUESTION 1 – THE EXTENT TO WHICH ANTEPARTUM HIV TRANSMISSION 
PREVENTION INTERVENTIONS CONTRIBUTE TOWARDS PREVENTION OF 
MOTHER-TO-CHILD TRANSMISSION OF HIV INFECTION 
It is believed that antepartum HIV transmission prevention interventions programmes 
have made a major contribution to prevent mother-to-child transmission of HIV 
infection. I would like to find out your perception towards Oshakati District Health 
Centre antepartum HIV transmission prevention interventions. 
No. Item Strongly 
Disagree 
Disagree Uncertain Agree Strongly 
Agree 
1 There is presence of high 
quality voluntary 
counselling and testing 
service. 
     
2 There is integration of 
highly active antiretroviral 
therapy services prioritized 
in antenatal services. 
     
3 There is community 
acceptance of HIV 
voluntary counseling, 
testing. 
     
4 Rapid HIV test is the first 
choice for routine testing. 
     
5 They use md-ARV for 
prevention of mother-to 
child transmission of HIV 
infection. 
     
6 HIV-infected pregnant 
women are counselled 
regarding the benefits of 
antiretroviral therapy for 
     
3 
 
prevention of perinatal 
transmission. 
7 Antiretroviral drugs are 
always available for 
interventions in reduction of 
HIV infection transmission. 
     
 
 
QUESTION 2 – THE EXTENT TO WHICH INTRAPARTUM HIV TRANSMISSION 
PREVENTION INTERVENTIONS CONTRIBUTE TOWARDS PREVENTION OF 
MOTHER-TO-CHILD TRANSMISSION OF HIV INFECTION 
It is believed that intrapartum HIV transmission prevention interventions programmes 
have made a major contribution to prevent mother-to-child transmission of HIV 
infection. I would like to find out your perception towards Oshakati District Health 
Centre intrapartum HIV transmission prevention interventions. 
No. Item Strongly 
Disagree 
Disagree Uncertain Agree Strongly 
Agree 
1 There are obstetrical 
interventions for prevention 
of mother-to-child 
transmission of HIV 
infection. 
     
2 There is administration of 
short course of AZT to 
pregnant mothers before 
birth in order to reduce HIV 
transmission. 
     
3 There is understanding and 
knowledge of the 
mechanism in the timing of 
preventing mother-to-child 
transmission of HIV 
infection. 
     
4 There is administration of 
short course monotherapy 
regimes from 36 weeks 
gestation to reduce HIV 
transmission. 
     
4 
 
5 HIV transmission is 
prevented by treating the 
pregnant woman during the 
third trimester, delivery and 
by giving the child 
prophylactic. 
     
6 HIV transmissions at 
different stages are 
prevented by the use of 
prophylactic interventions 
with combination of 
antiretroviral therapy. 
     
 
QUESTION 3 – THE EXTENT TO WHICH POSTPARTUM HIV TRANSMISSION 
PREVENTION INTERVENTIONS CONTRIBUTE TOWARDS PREVENTION OF 
MOTHER-TO-CHILD TRANSMISSION OF HIV INFECTION 
It is believed that postpartum HIV transmission prevention interventions programmes 
have made a major contribution to prevent mother-to-child transmission of HIV 
infection. I would like to find out your perception towards Oshakati District Health 
Centre     postpartum HIV transmission prevention interventions. 
No. Item Strongly 
Disagree 
Disagree Uncertain Agree Strongly 
Agree 
1 Women are educated 
about exclusive 
breastfeeding prior to 
delivery. 
     
2 Prevention of mother-to-
child transmission of HIV 
infection represents an 
entry point for improving 
overall family health. 
     
 
 





ANNEXTURE C: RESEARCH QUESTIONNAIRE FOR PATIENTS TRANSLATED 
IN OSHIWAMBO LANGAUGE 
OMAPULAAPULO KAAYAKULWA  GE NASHA NA NKENE OPROGRAMA 
YEKEELELO LYO MBUTO YOHIV OKUZA KUMEME OKUYA KOKANONA TAYI 
LONGO MPAKA MOSHAKATI 
 
OSHITOPOLWA SHA A 
Omauyelele go petameko ge na sha nomuyamukuli 
1 Onomola yomuyamukuli:  




3 Alikana ulika kutya ouli mongundu yoludhi lyuukwashigwana yini  




Ino hala oku holala oludhi lwoye  
 
4 Ulika kutya owuli mongundu yepipi lyeemvula dhini: 
Koshi yeemvula  20   
Pokati keemvula  20-30   
Pokati keemvula  31-40   
Pokati keemvula  41-50   
Eemvula 51 nenge dhi vulithe po  
 
OSHITOPOLWA SHA B  
OMALOMBWELO NKENE UNA OKUYAMUKULA OMAPULO 
GOMOSHITOPOLWA SHA B 
1 = Itandi tsu kumwe nande nande 
2 = Itandi tsu kumwe 
2 
 
3 = Kandishi wo naana 
4 =Otandi tsu kumwe 
5 = Otandi tsu kumwe lela lela 
 
Dhimbulukwa kutya kapena nana eyamukulo lya tali ka ko lya puka nenge 
lyomondjila momapulaapulo ngaka. Onkee ano yamukula omapulo ngaka  shii 
ikwatelela komaiyuvo goye mwene. 
 
EPULO 1 –NKENE OMIKALO DHOKUKEELELA ETAANDELO LYOMBUTO YO 
HIV, DHOKA HADHI LONGITHWA PETHIMBO MEME ELI METEGELELO TADHI 
KWATHELE MEKEELELO LYOMBUTO YO HIV OKUZA KUMEME OKUYA 
KOKANONA. 
 
Oshili sha itaalwa ko  kutya omikalo dhekeelelo lyombuto yo HIV okuza kumeme 
okuya kokanona odha kwathela lela moku keelela etaandelo lyombuto yo HIV okuza 
kumeme okuya kokanona. 
 Onda hala uku uva omaiyuvo goye kombinga yomikalo hadhi longithwa muka 
mOshakati dhekeelelo lyetaandelo lyo mbuto yo HIV okuza kumeme okuya 
kokanona pethimbo meme eli metegelelo. 
 
(Gandja  okangombe  √  mokakololo kehogololo lyoye) 

















neikonaakonitho lyo HIV 
hali ningwa moshakati 
olyo ngushu lela. 
     
2 Egandjo lyomiti dho 
kulelepeka oha li ningwa 
pamwe/mumwe 
nomathulo. 
     








lyakwalukehe, ata ku 
longithwa omukalo 
ngoka omuntu ta 
konakonwa nokumona 
eyamukulo lye pethimbo 
mpoka 
     
5 Oha ku longithwa omiti 
odhindji dho ARVs 
mekelelo lyombuto 
okuza kumeme okuya 
kokanona. 
     
6 Oomeme yeli 
momategelelo yo oyena 
ombuto yo HIV oha ya 
pewa ehungo mwenyo li 
nasha nuuwanawa 
womiti dhokulelepeka 




     
7 Omiti dhokulelepeka 
opo aluhe hadhi kala 
dhoka handi longithwa 
meshunitho pevi 
lyetaandelo lyo mbuto 
yo HIV. 




EPULO 2 – NKENE OMIKALO DHOKUKEELELA ETAANDELO LYOMBUTO YO 
HIV, DHOKA HADHI LONGITHWA PETHIMBO LYOKUPULUMUTHA TADHI 
KWATHELE MEKEELELO LYOMBUTO YO HIV OKUZA KUMEME OKUYA 
KOKANONA. 
Oshili sha itaalwa ko  kutya omikalo dhekeelelo lyombuto yo HIV okuza kumeme 
okuya kokanona odha kwathela lela moku keelela etaandelo lyombuto yo HIV okuza 
kumeme okuya kokanona. 
 Onda hala uku uva omaiyuvo goye kombinga yomikalo hadhi longithwa muka 
mOshakati dhekeelelo lyetaandelo lyo mbuto yo HIV okuza kumeme okuya 
kokanona pethimbo lyokupulumutha. 
(Gandja  okangombe  √  mokakololo kehogololo lyoye) 














1 Opena omikalo dhoka 
handi longithwa po ku 
valitha opo ku 
keelelwa etaandelo 
lyombuto yo HIV okuza 
kumeme okuya 
kokanona. 
     
2 Oomeme yeli 
momategelelo ohaya 
pewa omuti wo 
"AZT"manga inaya 
mona okanona opo ku 
shunithwe pevi ompito 
yetaandelo lyo HIV. 
     
3 Oku niwe euveko 
nuunongo nkene 
ekelelo lyombuto yo 
HIV okuza kumeme 
okuya kokanona hali 




4 Ohaku gandjwa omuti 
gumwe gwo AZT kuza 
peewike 36 opo ku 
shunithwe pevi 
oompito dhetaandelo 
lyombuto yo HIV okuya 
kokanona  
 
     
5 Etaandelo lyombuto 









     
6 Etaandelo lyombuto yo 
HIv ohali vulu oku 
keelelwa pompito 
dhayooloka ngele 
omuntu ta nu ehwata 
lyomiti dho ARV. 
     
 
EPULO 3 – NKENE OMIKALO DHOKUKEELELA ETAANDELO LYOMBUTO YO 
HIV, DHOKA HADHI LONGITHWA KONIMA YOKUPULUMUTHA TADHI 





Oshili sha itaalwa ko  kutya omikalo dhekeelelo lyombuto yo HIV okuza kumeme 
okuya kokanona odha kwathela lela moku keelela etaandelo lyombuto yo HIV okuza 
kumeme okuya kokanona. 
 Onda hala uku uva omaiyuvo goye kombinga yomikalo hadhi longithwa muka 
mOshakati dhekeelelo lyetaandelo lyo mbuto yo HIV okuza kumeme okuya 
kokanona konima yokupulumutha. 
(Gandja  okangombe  √  mokakololo kehogololo lyoye) 















1 Oomeme mboka taya 
lumbu nombuto yo HIV yeli 
momategelelo  oha ya 
longwa shina sha 
neyamutho lyokontulo alike 
o manga nokuli ina ya 
mona uunona 
 
     
2 Ekelelo lyombuto yo HIV 
okuza kumeme okuya 
kokanona osho osheelo 
okupitila moku hwepopeka 
uudjolowele waanegumbo 
ayehe. 
     
 
Tangi unene molwa ethimbo lyoye naasho wa kutha ombinga momapulapulo 
ngaka! 
 


















ANNEXTURE H: PATIENTS’ INFORMED CONSENT FORM 
 
 
 
 
